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Abstract 
Homeostasis of human T cells is regulated by many factors that control proliferation, 
differentiation of effector cells and generation of memory. Our current knowledge of the 
mechanisms controlling human T cell homeostasis in vivo is based on experiments in 
small animal models. However many differences exist between immune systems of mice 
and humans, including cell composition, function, and gene expression. Humanized 
mouse models have shown great value in the study of human immunobiology. I have 
used novel humanized mouse models to examine the role of human MHC (HLA) and 
human IL2 in CD8 T cell and CD4 regulatory T cell (Treg) homeostasis. To study human 
CD8 T cells I engrafted CD8 T cells from healthy donor PBMC into NOD-scid IL2rgnull 
(NSG) mice that lacked expression of murine MHC and that expressed HLA-A2. My data 
demonstrate that CD8 T cell survival and effector function required the presence of HLA-
A2, helper function from human CD4 T cells and exogenous human IL2. To study human 
Treg homeostasis I used NSG mice engrafted with human fetal thymus and hematopoietic 
stem cells (BLT model). NSG-BLT mice support the growth of human thymic tissue and 
enable the efficient development of HLA-restricted Treg and conventional T cells. Using 
an AAV vector to express human IL2, I demonstrated that functional human Treg but not 
conventional T cells increased in number in NSG-BLT mice and that this coincided with 
increases in activated human NK cells. Overall my research has revealed that HLA and 
human IL2 have an essential role in human T cell survival and function in vivo.  
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Chapter I – Introduction  
The immune system exists in a well-balanced state that is capable of remaining quiescent 
when not perturbed while also being poised to respond to foreign intrinsic “danger” 
signals that indicate the possible presence of an infection. Among the myriad of cells that 
make up the mammalian immune system, T cells stand out as an important part of both 
responding to infection and an opposite but just as important role in regulating the 
intensity of the response. Because of this duality, T cells are a popular target for 
therapeutic intervention to modulate immune responses.  The ultimate goal of my thesis 
research is to develop treatments that can either act alone or in conjunction with existing 
therapies to treat autoimmune conditions. Our knowledge regarding the cytokines and 
cell interactions that human T cells require for both normal homeostasis or when 
responding to foreign antigen in vivo is primarily based on experiments in rodent models. 
These experiments have discovered that a large portion of T cell function is conserved, 
but have also identified numerous differences between the human and mouse immune 
response. The many differences that exist between immune systems of mice and humans 
include cell composition, function, and gene expression (1). Because of these differences, 
there has been an effort to develop a small animal model to study human immunology. 
After decades of optimization, several strains of immunodeficient mice that are 
permissive to engraftment with human cells have been developed and utilized as the 
platform upon which the existing models have been built. In my experiments presented 
here, I have used several of these humanized mouse models to examine the role of human 
? ??
MHC and of different cytokines, specifically human IL-2 and IL-7, in CD8 T cell and 
CD4 regulatory T cell (Treg) homeostasis.  
 
To study human CD8 T cells, I used the NSG-PBL-SCID model and fractionated the 
whole PBMC fraction into distinct populations. Specifically, the NSG-PBL-SCID model 
used in most of these experiments was created using CD8 T cells that were isolated from 
PBMCs obtained from healthy donors. We injected the cells into NOD-scid IL2rgnull 
(NSG) mice that either expressed murine MHC-I, were deficient in MHC-I expression, or 
into mice that expressed transgenic forms of human MHC-I (HLA-A02*01). My data 
demonstrate that CD8 T cell effector functions are dependent upon the presence of either 
murine MHC-I expression or transgenic expression of human HLA-A02. Survival of 
these CD8 cells was also dependent upon the presence of a secondary cell population or 
the exogenous delivery of human IL-2.  
 
To study human Treg homeostasis I used the NSG-BLT mouse (Bone marrow Liver 
Thymus) model. BLT mice are created by transplanting a piece of human fetal thymus 
and liver under the kidney capsule. These mice are also injected with human CD34+ cells 
that are isolated from the fetal thymus. The human CD34+ cells expand and begin to 
produce myeloid and lymphoid cells. The T cell progenitor cells migrate to the human 
thymus organoid where they are educated on HLA. The BLT model was chosen for two 
specific reasons. First, the NSG-BLT mice support the growth of human thymic tissue 
and enable the efficient development of HLA-restricted T cells, and these mice develop 
? ??
stable populations of both Treg and conventional T cells. Using an AAV vector to 
express human IL2, I also demonstrated that functional human Treg, but not conventional 
T cells, increased in number in NSG-BLT mice and that this coincided with increases in 
activated human NK cells. Overall, my research has revealed that HLA and human IL2 
have an essential role in human T cell survival and function in vivo.  
 
Part 1: Innate immunity, T cell types and their respective roles role in the immune 
response  
 
Innate immunity 
Across many species, the immune system is made up of a number of cells that are both 
highly specialized and diverse in their mechanism of action. At the highest level, these 
immune cells can be broadly divided into two different domains that have distinct and 
complimentary roles; the innate and the adaptive immune systems (2). Both of these 
domains are essential to mounting a complete immune response, but the responses of 
these two domains are distinct in how they identify damage or infection, the nature of the 
response and the development of memory following activation. The primary distinction 
between these two domains lies in how foreign molecules or molecules that are indicative 
of non-apoptotic cell death or damage are sensed. Innate cells express receptors that are 
invariant and known as pattern recognition receptors (PRRs). These PRRs recognize 
several different motifs that are indicative of cellular damage or infection with a 
? ??
pathogen. The class of molecule that the PRRs can detect are referred to as either 
pathogen-associated molecular patterns  (PAMPs), if they are characteristically linked 
with infection or, damage-associated molecular patterns (DAMPs) if they are typically 
found after injury or non-apoptotic cell death (3). PAMPs are molecules that are either 
only found during infection or they are molecules that are found in a non-physiological 
location. Examples include lipopolysaccharide, peptidoglycan, flagella, ureic acid 
crystals, cytosolic DNA, or double-stranded RNA. DAMPs include molecules found after 
cells die due to injury or after they undergo necrosis. Typical DAMPs include cytosolic 
DNA, or the chromatin-associated protein HMGB1. Both stimulate a strong immune 
response when sensed in the cell in a non-physiologic location. There is some overlap 
between these groups as both damage or infection may result in the presence of cytosolic 
DNA, for instance. Also, TLR4 recognizes LPS as well as heat shock proteins, making it 
capable of recognizing both PAMPs and DAMPs.  A list of common PRRs, their primary 
location, and primary ligand can be found in Table 1.  
 
  
? ??
Table 1: PRRs, their location and their ligands 
????????? ????????? ??? ??????????? ??????
????? ????????? ???????????? ?????
?????? ????????? ???? ?????
????? ????????? ??????????
??????????
?????
????? ?????????????? ?????? ?????
????? ?????????????? ?????????????? ?????
????? ?????????????? ???????? ?????
????? ?????????????? ??????????
??????????
??????
????????? ?????????????? ???? ??????
????? ??????????????? ???? ??????????
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The innate immune system consists primarily of cells that belong to the myeloid lineage. 
However, some of the cells of the innate immune system are of lymphoid origin. For 
example, NK cells and ILCs (innate lymphoid cells) are activated by invariant receptors 
that sense danger or they respond to signals that indicate stress in other cells and develop 
from lymphoid progenitor cells (14). Other innate lymphoid cells such as B-1 cells (15) 
and γδT cells (16) express receptors with limited variability, but lack the ability to 
generate a memory response following activation. While some of these innate cells are 
specialized in direct killing, sequestration of pathogens, or secretion of histamine, others 
are more specialized in antigen presentation (17). Not only do they process proteins and 
present antigens in the context of the MHC-I and MHC-II molecules, they also provide 
co-stimulation, cytokines and chemokines that recruit the cells of the adaptive immune 
response to the relevant areas. 
 
Antigen presentation is a crucial step in both activating and regulating the second 
“adaptive” domain of the immune system. Of these innate cells, DCs are particularly 
important in maintaining tolerance as well as activating the immune system under 
inflammatory circumstances (18). Immature DCs migrate from lymphoid tissues through 
peripheral tissues where they take up and present antigen (19, 20). Most of these antigens 
that the DC samples from the environment come from the normal apoptotic-turnover of 
cells and is important for maintaining overall peripheral tolerance (19, 21). Antigen 
presentation by non-inflammatory DC is crucial in the development of tolerance through 
several different mechanisms (22). T cells that bind to these apoptotic antigens can 
? ??
become anergic (23), can be induced to undergo apoptotic cell death (24), or can cause 
the T cell to develop into a Treg (25). Under inflammatory conditions, mature DCs are 
also vital for the normal development of the immune response (26).  As these DC migrate 
from the periphery to secondary lymphoid tissue,  they undergo a specific maturation 
process that results in a number of changes that enhance the DCs ability to activate T 
cells. DCs constitutively express moderate levels of the immunoproteasome, an enhanced 
form of the normal cellular proteasome that processes proteins for antigen presentation 
(27). As they mature, DC expression of the immunoproteasome increases beyond normal 
levels (28, 29). They begin to express chemokine receptors that facilitate migration to the 
secondary lymphoid organs and they express more co-stimulatory molecules (30). 
 
While during steady-state conditions, the circulating DCs are immunosuppressive, during 
inflammation they mature into a state that activates the adaptive immune system. This is 
largely due to changes that occur during DC maturation following the exposure to 
microbial PAMPs or endogenous DAMPs (31). These signals trigger an increase in the 
expression of MHC and increase the expression of co-stimulatory molecules such as 
CD80 and CD86 (32), chemokines (33, 34), and receptors that promote migration into the 
secondary lymphoid organs (35, 36). Within the T cell zone of lymph node germinal 
centers, the DC present these antigens to naïve T cells and stimulate the development of 
effector functions and proliferation (37). Rapid activation in response to conserved 
molecular patterns allows the innate immune system to quickly respond to potential 
threats through direct killing, cytokine production and antigen presentation. 
? ??
Table 2: Co-Stimulatory molecules, their ligands, and the effect on T cell activation 
????????? ???????
? ????????
????????????????????????? ??????
???? ????? ?? ??????????
???? ????? ?? ??????
????? ?????????? ?? ??????????
????? ?????? ?? ??????
????? ????? ?? ??????????
?????? ?????????? ?? ??????????
????? ??????? ?? ??????
???? ?????? ?? ??????
?? ?? ????? ?? ??????
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Table 2: Co-Stimulatory molecules, their ligands, and the effect on T cell activation 
T cells can express a number of receptors that bind to ligands that may exist at the 
immunological synapse, depending on the current conditions within the immune 
system. When the receptor binds to the associated ligand(s), there can be an increase 
in cell activation or proliferation that can function as “signal 2” during T cell 
activation. Alternatively, the ligand-receptor pairing can result in a diminution of 
the immune response.  
 
?
?
  
? ??
Adaptive immunity  
The adaptive immune system is largely dependent upon antigen presentation, much of 
which occurs on specialized APC within the innate immune system. The cells that make 
up the adaptive immune system are divided into T cells and B cells. Both of these cell 
lineages, like the cells of the innate immune system, are capable of recognizing foreign 
antigen. However, T cells and B cells differ in that they do not respond to foreign antigen 
directly through invariant receptors but by specialized receptors. The common 
distinguishing feature of these B and T cell receptors is that they develop through a 
process of genetic recombination and mutation that expands the number of potential 
epitopes that can be recognized beyond what can be encoded in the genome (51). B cells 
recognize foreign antigen, in a soluble form or expressed on a cell surface with a 
membrane bound BCR and also function as an APC by presenting antigen to T cells (52). 
BCR engagement with foreign antigen and appropriate co-stimulation activates the B 
cells and results in the production and secretion of antibody (53). Following antigen 
exposure, B cells migrate to germinal centers where they undergo maturation and a 
process called somatic hypermutation (SHM) that results in the B cells becoming 
antibody-producing plasma cells (54). In addition to SHM, these cells undergo a second 
process called class switch recombination (55, 56). Antibodies exist as a number of 
different isotypes that differ in the constant region. During CSR, the variable region of 
the antibody heavy chain is unchanged but the constant region of the heavy chain is 
alternatively spliced resulting in the production of antibodies with a different constant 
region (57).  
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Both plasma cells and the memory B cells that produce antibodies are long lived. This 
long-lived nature makes antibody production an essential component of long-term 
immunity. Because of this, the vast majority of vaccine design and development has 
focused on developing a B cell response to confer long term immunity (58, 59). B cells 
and the isotype switching that occurs is ultimately dependent upon T cell help from a 
specialized type of CD4 T cell called a T follicular helper cell (Tfh) (60).  
 
T cells express a membrane-bound receptor that is responsible for the T cells ability to 
recognize and respond to foreign antigen. This TCR is a heterodimer made up of an alpha 
and a beta chain that associate in the plasma membrane with either the co-receptor CD4 
or CD8. The expression of CD4 or CD8 divides T cells into two distinct categories that 
are named for the co-receptor that they express. Unlike the BCR, the TCR does not 
recognize foreign antigens directly. Instead, the TCR binds to peptides that are presented 
by a complex of proteins called the MHC.  CD4 T cells, also known as helper T cells 
(Th), recognize antigen presented by MHC-II and secrete cytokines which are responsible 
for many regulatory effects. CD8 T cells are primarily cytotoxic cells and kill cells that 
express antigen on MHC-I molecules (61). For both of these cell types, the TCR 
recognize short peptide antigens that have been processed from protein and presented by 
specialized MHC molecules found on the surface of APCs (MHC-I and II) and most 
somatic cells (MHC I) (62). In general, peptides that arise from proteins that are produced 
within the cell are presented via MHC-I (63). Peptides that arise from exogenous proteins 
that are taken up by phagocytosis and processed by both the phagolysosome and the 
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proteasome and the peptide fragments that are produced are then presented within the 
MHC-II complex (64). Although the majority of phagocytosed antigens are processed 
and presented by MHC-II, these antigens can also be presented by MHC-I in a process 
called cross-presentation (65). MHC-I consists of two proteins, an integral membrane 
protein that binds to and presents the peptide to the T cell, and the B2M protein (66). 
Proteins processed in the proteasome complex and subsequently presented in a binding 
groove formed by the α1 and α2 subunits and are presented at the cell surface for 
recognition (67).   
 
Both CD4 and CD8 T cells depend on TCR-MHC interactions to mediate their effects, 
but TCR binding to MHC is insufficient to cause T cell activation. T cells depend on 
three signals for activation (68). The first signal is the antigen-specific interaction 
between the TCR on the surface of the T cell and a MHC molecule on the surface of an 
APC (69). The second signal is provided by co-stimulatory molecules that are expressed 
in conjunction with the MHC-I binding to its receptor on the surface of the T cell. The 
classic example of co-stimulation is CD28 expressed by T cells binding to CD80/CD86 
on an APC (70, 71) but numerous other molecules exist that are capable of acting as a 
second signal for activation and are listed as ligands in Table 2. Finally, certain cytokines 
can provide the third signal necessary for T cell activation. Frequently type I interferon 
(IFNα and IFNβ) and IL-12 act as a third signal (72, 73) .   
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Along with their different MHC preference, these two main subsets of T cells have 
different functions within the immune response. In mice, CD8 T cells are primarily 
cytotoxic cells and are the T cell type responsible for cellular immunity.  These cells 
function by binding to peptide presented by MHC-I with their TCR. MHC-I is expressed 
on most cells and it generally presents antigen found within the cell (63). Consequently, 
CD8 T cells will recognize cells that present intracellular foreign antigens on their 
surface. During an infection, intracellular pathogen-derived proteins will be processed 
and presented on the surface of the cell.  After recognizing these foreign proteins, a CD8 
T cell will undergo a clonal expansion that produces both effector and memory precursor 
cells (74). The effector cells in particular will then mediate the cytotoxic functions that 
are characteristic of this cell type. After recognizing infected cells, CD8 T cells will 
release cytotoxic granules that contain the proteins such as perforin (Prf) and granzyme B 
(GzB)  that ultimately lead to the apoptotic death of the target cell (75). Additionally, 
CD8 T cells may kill target cells through the expression of FasL, which binds to Fas 
expressed on target cells, and also triggers apoptotic cell death (76-78). CD8 T cells also 
produce a number of cytokines that are important for the immune response such as IFNγ. 
CD8 T cells that are activated in the presence of IL-12 tend to produce IFNγ (79). Certain 
subsets of CD8 T cells may also play a regulatory role. For example, Qa-1-restricted CD8 
T cells have been demonstrated to be crucial for regulating CD4 T cells. Qa-1 or HLA-E 
is engaged by NKG2A/CD94 respectively and leads to an inhibition of activity on the 
conjugate CD4 T cell (80).   
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CD4 T cells are often also called “helper T cells.” This name reflects the role that they 
play upon activation which is primarily that of a regulator. CD4 T cells bind to antigen 
that is presented by specialized APCs that express MHC-II and help to regulate the 
immune response (64). Naïve helper T cells have the ability to react to the wider context 
of the immune response (typically the cytokines that are present at the time of activation) 
in order to mature into several different subsets of cells. When mature, CD4 T cells can 
mediate either positive or negative effects in a number of other cell types. Th cells are 
classically divided into Th1 and Th2 subtypes (81). In this model, a naïve CD4 T cell 
encounters a cognate antigen expressed by MHC-II molecule and specialization to Th1 or 
Th2 is guided through the presence of different cytokines. These distinct subsets are 
defined by specific cytokines expressed by the Th cells and by the overall impact the 
cytokine profile has on the immune response. Naïve CD4 T cells that encounter a cognate 
antigen presented by MHC-II will mature into Th1 cells in the presence of IFN- γ (82) 
and IL-12 (83) and into a Th2 cell in the presence of IL-4 (84) and IL-2 (85). Th1 cells 
primarily mediate functions that are related to cellular immunity, specifically producing 
cytokines that enhance the CD8 T cell response. Th2 cells are classically involved in 
humoral immunity and are crucial in facilitating B cell maturation and antibody class 
switching (86). Although the Th1/Th2 paradigm is a useful description, recent findings 
have necessitated an expansion of these categories to include newly described subsets 
that do not fit within these categories. Th9, Th17, Th22, and Treg cells all fall outside of 
the classical paradigm in that they are induced by different cytokines (Figure 1B) and 
have functions that differ from either Th1 or Th2 cells (Figure 1D) (87). Th9 cells 
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produce IL-9 and IL-21 and have been identified as a possible cell type that is involved in 
several different autoimmune conditions (88).  IL-9 was initially classified as a Th2 
cytokine until evidence suggested that there was a subset of presumed Th2 cells that 
produced IL-9 preferentially and were induced to do so in the presence of TGFb (88, 89). 
Although only recently discovered, this subset has been classified as a primarily pro-
inflammatory cell type and linked to anti-tumor effects (90) as well as being increased in 
allergic patients (91) or in a mouse model of airway inflammation (92). Th17 cells are 
identified by the expression of the transcription factor RORγt (Figure 1C) and produce 
the cytokines IL-17, IL-22, and IL-25 (Figure 1D) (93). Initially, these cells were 
identified in a number of autoimmune conditions as well as in the inflammatory response 
to opportunistic infections by normally commensal bacteria and fungi. However, these 
cells have proven difficult to study due to a high degree of plasticity. For instance, in 
autoimmune models such as EAE, Th17 cells were shown to undergo changes during the 
inflammatory response that led to the expression of cytokines that were considered non-
Th17 (94).  Th22 cells bear a number of similarities to Th17 cells. Like Th17 cells, Th22 
are highly associated with inflammation in autoimmune diseases (95, 96). Likewise, 
Th22 and IL-22 are both linked with preventing overgrowth, inflammation and infection 
from commensal bacteria (97).  
 
CD4 Treg are distinct from other Th subtypes in that their primary purpose is to dampen 
the immune response under inflammatory conditions and to maintain tolerance under 
normal circumstances (98). Although other Th subtypes can be immunosuppressive in 
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certain contexts, the primary purpose of Treg is to limit the immune response to foreign 
antigen during infection and to prevent autoimmune reactions to self-peptides (99). 
Furthermore, Treg have specific requirements for survival. Unlike conventional cells that 
primarily depend upon IL-7 for survival, Treg primarily depend upon IL-2 for both 
survival and function through the maintenance of the master Treg transcription factor 
FoxP3 (100, 101). Signaling through IL-2 promotes the expression of stat5 and maintains 
the expression of Foxp3 (102, 103). This role for IL-2 in promoting survival of Treg 
provides a feedback loop where activated T cells produce more IL-2 (104, 105). 
Increased IL-2 promotes Treg function and proliferation which, in turn, limits the 
immune response.  
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Figure 1: The cytokine milieu present during activation determines terminal 
effector fate of naïve CD4 cells 
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Figure 1: The cytokine milieu present during activation determines terminal 
effector fate of naïve CD4 cells  
Naïve CD4 T cells circulate through the tissues of the body and the secondary 
lymphoid organs. When these naïve cells (A) encounter antigen under inflammatory 
conditions they mature into a specialized cell type. This directed development occurs 
based on the cytokine milieu that they are exposed to during activation (B). These 
CD4 cells mature when binding to conjugate antigens expressed by APCs. During 
inflammatory conditions, these cells undergo changes into specific subtypes and can 
be identified by both the expression of certain transcription factors (C) and, to an 
extent, the cytokines that they can produce (D) following maturation. 
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Part 2: The development, homeostatic proliferation and the function of T cells 
Development of T cells in the Thymus and Central Tolerance 
T cells develop in a well-regulated pattern that is optimized for producing cells that meet 
two conditions. First, these T cells must have an inherent affinity for the peptide-MHC 
complex. This MHC restriction ensures that the T cells will capable of recognizing 
antigen within the context of MHC-1 and II. Second, these T cells must be tolerant to 
endogenous self-antigens to prevent autoimmune activation. This thymic regulation is 
referred to as central tolerance and is divided into positive selection and negative 
selection respectively (106). The result of this development and selection is the 
expression of a TCR where both the α and β chains have been rearranged through a 
process of recombination within the TCR locus. The selection process begins with 
common lymphoid progenitor cells migrating into the cortex of the thymus. At this stage, 
these cells do not express either CD4 or CD8 (double negative) (Figure 2A). 
Development in these pre-T cells begins with the expression of an invariant α-chain and 
the rearrangement and mutation of the β-chain locus. Not all cells will produce a 
functional β-chain capable of pairing with the invariant α-chain at this stage. Those that 
do produce a functional β-chain (Figure 2B) proliferate and progress to the next stage in 
development whereas those that do not will be eliminated (Figure 2C). Signaling through 
this pre-TCR stops recombination at the β-loci, induces proliferation and promotes the 
expression of both the CD4 and CD8 co-receptors. At this next stage, recombination 
occurs at the α-locus in the pre-T cell. Once again, survival and proliferation of the cell 
depends upon the successful rearrangement of the α-locus. First, the rearranged α chain 
? ??
must be capable of pairing with the rearranged β-chain (Figure 2D). Inability to pair with 
the β-chain results in the elimination of the T cell (Figure 2E).  
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Figure 2: The thymic development of CD4 and CD8 T cells 
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Figure 2: The thymic development of CD4 and CD8 T cells 
DN thymocytes migrate into the thymus where they begin to express an invariant α 
chain of the TCR (A.). The β-locus of the TCR undergoes recombination. Successful 
rearrangements of the β-locus can pair with the invariant α chain and progress to 
the DP stage (B.). Unsuccessful recombination results in deletion of the pre-T cell 
(C.). Signaling through the pre-TCR causes rearrangement of the β-locus to stop 
and the expression of CD4 and CD8. These DP T cells proliferate and begin 
recombination at the α-locus. (D. and E.). Loci that successfully undergo 
recombination must be able to pair with the β-chain. Successful pairing results in 
survival (D.) whereas an inability to pair results in elimination (E.) 
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This α/β TCR must now be capable of pairing with and recognizing either MHC-I or II in 
the process referred to as positive selection. The thymocytes expressing both CD4 and 
CD8 are exposed to self-antigens presented by MHC-I and MHC-II molecules on cTEC 
(Figure 3A and 3B). T cells must express a TCR that has some inherent affinity for the 
MHC-peptide complex in order to function properly. Cells that have little or no affinity 
die through the induction of apoptosis (Figure 3A and 3B). Those DP cells that have a 
high affinity for MHC-I complexes downregulate CD4 (Figure 3C) whereas those that 
have a high affinity for MHC-II downregulate CD8 (Figure 3D) (107). At this stage, the 
thymocytes now express either CD4 or CD8 and express a TCR that has an inherent 
affinity for the MHC-peptide complex. These cells are educated on endogenous peptides 
and because of this, there is the distinct possibility for these T cells to cause an 
autoimmune reaction if they migrate into the periphery. To prevent this, the T cells must 
undergo another stage of development, negative selection, where the cells with too high 
an affinity are eliminated. In the medulla, these cells encounter medullary thymic 
epithelial cells (mTECs) that express a specialized transcription factor, AIRE, that 
controls expression of tissue-specific antigens (108). AIRE-expressing mTECs produce 
proteins found throughout the body that are usually only expressed by specialized cells. 
CD8 and CD4 T cells that bind MHC-I or II with a high affinity die by apoptotic cell 
death or are induced to become Treg. Those with an intermediate affinity survive and 
emigrate into the periphery to become naïve CD8 (Figure 3E) or CD4 (Figure 3F) cells. 
Treg development is different from conventional T cell development in a number of ways 
that begins when CD4 T cells undergo negative selection.  
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Figure 3: T cells are educated on endogenous peptides expressed on both mTEC and 
cTEC.
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Figure 3: T cells are educated on endogenous peptides expressed on both mTEC and 
cTEC. 
Following rearrangement of the α and β loci, the TCR must recognize either MHC-I 
(A.) or II (B.) MHC. During positive selection, T cells that express a TCR that lacks 
affinity for MHC-peptide complexes expressed on cortical thymic epithelial cells 
(cTECs) die due to neglect (B. and D.). During Negative selection, cells that have too 
high of an affinity for MHC-peptide complexes are deleted through apoptosis. T 
cells with an affinity for MHC-I will develop into CD8 (F.) whereas those that 
recognize MHC-II will develop into CD4 (E.). 
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Treg Development in the Thymus and the Periphery 
CD4 Treg can develop in either the thymus or in the periphery and are respectively 
referred to as natural or induced Treg (109). Along with the “central tolerance” that 
occurs during development in the thymus, Treg play a vital role in “peripheral tolerance” 
and are essential to prevent aberrant activation. Although central tolerance is vital to the 
maintenance of tolerance, an estimated 25-40% of T cells that emigrate from the thymus 
are cells that have escaped clonal deletion (110). Mutations in FoxP3 were first identified 
in “scurfy” mice that develop a fatal lymphoproliferative disease (111). In humans, 
mutations in FoxP3 that impact Treg development and function also results in a fatal 
lymphoproliferative condition known as IPEX (112). The initial development of Treg in 
the thymus follows the same pattern of selection that conventional T cells undergo. The T 
cells with no or little affinity for the peptide MHC complex die from neglect. The 
difference emerges during positive selection when T cells with high avidity to MHC-self 
complexes are typically deleted (113). Some of these high-avidity cells are instead 
preserved, induced to produce the transcription factor FoxP3, and become regulatory T 
cells (114).  These cells emigrate from the thymus and are essential to maintaining a 
tolerogenic state and preventing aberrant activation.   
 
Once mature T cells emigrate from the thymus, they are nominally tolerant of 
endogenous antigens. However, potentially self-reactive T cells regularly escape deletion 
and migrate into the periphery (115).  
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Peripheral Homeostasis and Survival of Tconv and Treg 
After T cells complete the developmental process in the thymus, naïve CD4 and CD8 T 
cells emigrate from the thymus and into the periphery where survival is then dependent 
upon two different factors. First, the naïve T cell must encounter and bind with peptide-
MHC complexes to survive (116, 117). While migrating through the periphery under 
normal conditions, these naïve cells come into contact with APCs and stromal cells 
(MHC-I) that express self-peptide-MHC complexes. If the ability to signal through the 
TCR is impaired experimentally by deleting downstream signaling molecules there is a 
noticeable shortening of the lifespan in these cells compared to T cells that are capable of 
signaling through the TCR (118). Both CD4 (119) and CD8 (116) T cells require a 
constant low level of stimulation through the TCR. The second signal required for 
survival is provided by cytokines. Primarily, these naïve cells depend upon IL-7 for 
survival but both IL-15 and IL-2 also contribute to survival and proliferation (120). IL-7 
was shown to be vital for the survival of naïve cells. A total lack of IL-7 results in a loss 
of naïve cells whereas overexpression of IL-7 causes higher than physiological levels 
(121, 122). IL-7 binds to the IL-7R complex composed of CD127 and IL2Rγc and signals 
through stat5 (123). Under steady-state conditions, IL-2 is required only for Treg 
survival. Finally, IL-15 is particularly important for the maintenance of normal 
homeostasis of memory CD8 T cell levels (120, 124). IL-15 is different from most 
cytokines in that it is not secreted and instead it is membrane bound and it binds to the 
IL-15R at an immunological synapse (125).  
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The migratory path of naïve T cells and the initiation of the T cell response to 
foreign antigen.  
 
T cells that have emigrated from the thymus survive because of constant MHC 
stimulation and due to a select few necessary cytokines that are normally present. The 
naïve phenotype of these cells is characterized by the presence of a number of markers 
such as CD45RA, CD62L and CCR7 (126, 127). The latter of these two facilitate homing 
and migration into secondary lymphoid organs. CD62L (also called L selectin) facilitates 
the entry of T cells into the secondary lymphoid organs by binding CD34 or GlyCAM-1 
and slowing the flow rate of these cells through the blood vessels (128). Likewise, CCR7 
is expressed on naïve cells and it binds to chemokines that are preferentially produced in 
secondary lymphoid organs (129). This receptor also facilitates the overall movement of 
the naïve T cells towards lymph nodes. Lymph nodes are collection points that drain 
tissues and concentrate antigen through the migration of tissue resident macrophages and 
dendritic cells. Naïve T cells are then exposed to these antigens and, in the case of 
infection, T cells that can recognize the foreign antigen activate and begin to multiply 
(129).  
 
Memory T cell development 
Following exposure to antigen in the periphery, T cells begin to undergo profound 
changes that begin with the upregulation of certain proteins and an increase in 
proliferation called clonal expansion. This expansion gives rise to a population of T cells 
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that all have the capability of recognizing the same foreign antigen. Due to differences in 
cell division, co-stimulation and cytokine stimulation, these cells give rise to a non-
homogenous population of T cells that, although they share a common TCR, are 
specialized for different roles in the T cell response. Historically, this division gave rise 
to two populations that are largely differentiated by their migratory patterns and the 
effector functions the T effector memory (TEM) and the T central memory (TCM) cells 
(130). TEMs migrate from lymphoid organs and into tissues where they mediate the 
effector functions seen during the acute immune response whereas the TCMs recirculate 
throughout the lymphatic system. More recently, however, this paradigm has changed to 
include a number of other possible fates and specialties including tissue-resident memory 
cells (TRMs), short lived effector cells (SLECs) and memory precursor effector cells 
(MPECs) (131). The effector memory cells proliferate quickly, upregulate effector 
proteins used to combat the infection, and migrate into the periphery to areas of infection 
(132). At the end of the immune response, the SLEC population undergoes contraction 
through a process of apoptosis mediated by Bim and FAS-FASL that eliminates the vast 
majority of the cells (133-135). Central memory cells are more resistant to death during 
this phase and persist long-term after the immune response has resolved and returned to a 
point of homeostasis (136-138).  
Part 3: Graft versus host disease 
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GVHD is a Complication of Tissue Transplantation 
Tissue transplantation is often the definitive treatment for a number of diseases but it is a 
treatment that is not without risks. One such complication is graft versus host disease 
(GVHD). Three factors determine the risk for GVHD to develop in a transplant recipient. 
First, the tissue or organ from a donor individual will introduce some number of 
passenger lymphocytes into the recipient of the graft. The amount of donor cells 
transferred varies greatly depending on what is transplanted. In healthy individuals with 
complete immune systems, these passenger lymphocytes are quickly eliminated and pose 
no risk to the recipient individual. The second condition necessary for GVHD, is that the 
recipient of the transplanted tissue must be incapable of rejecting the transplanted 
lymphocytes. As transplant patients typically undergo a regimen of immunosuppression 
along with transplantation, it is frequently the case that graft recipients cannot reject the 
transplanted cells (139). Finally, the transplanted lymphocytes must recognize the 
recipient’s tissues as foreign, become activated and mediate an immune response against 
the host tissues (140). Collectively, these three conditions result in a condition known as 
graft versus host disease (GVHD) (141). Donor cells from the same species mediate an 
allogeneic graft versus host response but cell transplants across species can mediate a 
similar disease state referred to as xenogeneic graft versus host disease. Although 
possible with most transplantations, GVHD occurs most frequently in patients that have 
undergone HSC transplantation from either a related or an unrelated donor (142). 
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The TCR has an inherent affinity for the MHC that is finely tuned during T cell 
development in the thymus. Cells possessing TCRs that have no affinity for MHC are 
eliminated and those with excessive affinity are also eliminated via positive and negative 
selection respectively. In an allogeneic or xenogeneic environment, the TCR maintains a 
strong innate affinity for the MHC that is expressed by the host. However, the donor T 
cells that are active in GVHD have not undergone central tolerance with regards to the 
host MHC and, as a result, highly reactive TCR (TCR that bind with high avidity) have 
not been eliminated. Similar to this, antigens that are presented by the passenger APC can 
also cause a different reaction. Polymorphisms that exist between individuals (allogeneic-
GVHD) or species (xenogeneic-GVHD) can also elicit an immune response. This is not 
directly related to the structure of the MHC and is instead related to differences in the 
protein structure and sequence  that is presented by MHC-I and II (143). 
 
The Phases in the Development of acute GVHD 
GVHD occurs in 3 distinct phases: the afferent, the efferent and the effector phase (144). 
The cytokines and cells involved and the resulting pathology are different and are used to 
distinguish each phase.  The afferent phase occurs first and is often described as a 
priming step where the Th cell types in particular become activated. Patients who are 
undergoing bone marrow grafts are treated with myeloablative chemotherapy or 
irradiation to eliminate the endogenous hematopoietic stem cells (HSC) (145). These 
cause widespread tissue damage that results in inflammation through the presence of 
DAMPs and PAMPs leading to the activation of the innate immune cells, and the 
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secretion of type I interferon. This collectively leads to the maturation of APCs and these 
cells become primed to present antigen to incoming T cells while the overall cytokine 
milieu is one that is conducive to T cell proliferation and activation. The efferent phase 
occurs after the T cells have recognized the foreign antigen and begin to traffic into the 
host tissues and proliferate. This phase positions the T cells in the tissues that will be 
damaged in the final stage of GVHD. The final stage in GVHD, called the effector phase, 
involves T cell activation causing damage to the host cells. Here, the T cells that were 
primed/activated during the afferent phase begin to cause direct damage to the host 
tissues. Classically, the skin, liver and intestinal tract are most affected by this damage 
but the kidneys as well as the lungs may also be damaged during this phase (146).  
Chronic and mixed forms of GVHD   
The time of manifestation after transplantation determine whether the symptoms were 
indicative of acute (aGVHD) or chronic (cGVHD). Commonly, aGVHD is defined as 
occurring within the first 100 days after transplantation and cGVHD after the 100-day 
mark. This classical division is not an absolute and there are common examples of 
GVHD that bear characteristics of the aGVHD that occur years after transplant and 
concurrent with a cGVHD type disease (147). There is considerable overlap in the organ 
systems that are impacted but cGVHD typically occurs in a wider range of tissues unlike 
in aGVHD which typically develops in a predictable pattern, cGVHD can manifest in a 
number of different ways and with a less predictable course to the overall disease. Also 
different is that many cGVHD cases seem to mimic symptoms or pathological findings 
that are typically seen in autoimmune diseases. Frequently, patients develop 
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autoantibodies such as anti-nuclear antibodies typical of lupus (148) or skin lesions that 
are identical to scleroderma (149). Both conditions are unfortunately common 
particularly within HSC recipients. Overall mortality is high among HSC recipients, but 
aGVHD is responsible for 40% of that overall mortality (142). Chronic GVHD occurs in 
44% of all HSC transplantation and is the leading cause of mortality (147). 
   
Part 4: Gene therapy 
 
A Complicated History With Mixed Results 
Since the concept of genetic inheritance was developed, scientists have endeavored to 
find ways to alter this inheritance to achieve specific goals. Historically, this took place 
through such practices as animal husbandry and the intentional breeding of plants to 
encourage desirable traits. Specifically, there is evidence that dogs (150), horses (151), 
sheep (152), and cattle (153-155) have undergone intentional genetic manipulation 
through breeding. Once the molecule responsible for inheritance was identified this idea 
matured into inducing changes in DNA directly. At first, such attempts were crude 
random exposure to mutagens or radiation to hopefully cause some beneficial mutation 
(156-158). Bacterial cultures were exposed to chemical mutagens (alkylating agents such 
as ethyl methanesulfonate) and for a time, plants were grown in so called “atomic 
gardens” or directly exposed to γ radiation. Although crude, some of the most popular 
plant varieties that exist today, most notably Rio red grapefruit and most varieties of 
peppermint were developed through this shotgun approach (156). Clearly though, this 
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approach was less than ideal for two primary reasons. First, this random approach was 
labor intensive and of overall questionable value due to the random nature. Second, such 
approaches would be untenable as a possible treatment or for medical use in people.  
   
A significant breakthrough for the application of genetic modification was the 
development of the gene gun as a method to physically deliver DNA into the surface 
areas of plants (159). So called metal “microprojectiles” were coated with nucleic acids 
and propelled into plant cells through the cell wall by modifying a pneumatic airgun. 
Dubbed a “biolistic” (biological-ballistic), this approach lead to transient expression of 
genes in several different mono and dicotyledonous plants. Later, this approach was 
attempted with mammals in an attempt to adapt the technology for human use with the 
research focusing primarily on the application of genetic vaccines (160). The next logical 
step was to find a way to adapt this technology to treat genetic disorders. Many such 
genetic diseases result from genetic mutations that either lead to a loss of function in the 
resulting protein or an alteration that causes impaired or unsuccessful 
transcription/translation (161). In either case, definitive treatment would be to deliver a 
replacement DNA segment for the defective protein. These defects can be difficult to 
treat with conventional therapies for a number of reasons. For instance, replacing a 
missing membrane or mitochondrial protein is difficult to deliver due to location of the 
affected protein, as is the case in cystic fibrosis (162). Even if the defective protein can be 
delivered effectively, such treatments are frequently costly. An example of this is enzyme 
replacement therapy for lysosomal storage disorders, which require frequent infusions 
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that are expensive and have limited shelf-life, such as Fabry (163) and Gaucher (164) 
diseases. In both cases, the ideal treatment would be to either repair the defective gene or 
to deliver a replacement gene that expresses a physiological amount of the defective gene 
product. This approach presents a number of challenges. After identifying the defective 
gene, the first obstacle is to find a way to deliver genetic material to the desired cell type 
or organ and to ensure that the delivered genes are expressed.   
 
To overcome this first obstacle, different approaches have been developed. First, the 
genes can be delivered by direct injection; cells may be transformed in vitro before they 
are injected, or by pneumatic delivery (gene gun) (165). These methods are limited and 
typically confined to targeting those cells from a limited subset of tissues that are either 
easily accessible or can be removed and transduced ex vivo. Alternative approaches have 
involved using promoters that allow expression only in dendritic cells (DC). Delivery of 
genetic material to the skin results only in expression in DC as opposed to all cells in the 
vicinity of the gene gun delivery area (166-168). This approach is somewhat limited in 
what tissues can be targeted. Subsequent approaches are more diverse in the tissues that 
can be targeted for transformation. 
 
An alternative and more-targeted approach is using viruses to deliver the genes either 
directly or in vitro before transferring into a recipient host. Such approaches have been 
successful in treating human diseases (adenosine deaminase deficiency induced severe 
combined immunodeficiency) (169). Viruses are potentially immunogenic and previous 
? ??
gene therapy interventions, specifically one treating ornithine transcarbamylase 
deficiency, have resulted in fatalities (170). Despite this risk, different viruses have 
different tropisms and this specificity allows for the targeting of certain cell-types based 
on which cells are permissive to infection with a given virus (171-173). Because of this, 
viruses can be chosen to deliver genes based on the cell type that is permissive to 
infection. Furthermore, viruses possess the necessary proteins to facilitate integration of 
the replacement gene into the host genome (in the case of retroviruses) or to persist long-
term in an extrachromosomal state (AAV).   
 
Viral Vectors as Adaptive Gene-Delivery Tools 
Many viral vectors have been used to deliver genes. The cells that can be modified for 
any given virus are limited to those who are permissive to infection as viruses depend on 
different receptors for cell entry. Research has focused on herpesvirus, lentivirus, 
adenovirus, and adeno-associated viruses (174). Lentiviruses have a strong preference for 
infecting dividing cells, specifically preferring to infect leukocytes in many cases both in 
vivo and in vitro. Genes delivered through this vector can integrate into the genome 
where the delivered gene is maintained despite the frequent division (175). Many of the 
human trials that have been done in gene therapy have used lentivirus as a vector. 
Likewise, adeno-associated viruses have also been used to deliver genetic material to a 
wider variety of target cells for a number of reasons. Primarily, these viruses are 
replication defective and are not known to cause any sort of productive infection or 
disease (176). Interestingly, although not known to cause any human diseases, a large 
? ??
portion of the human population has antibodies specific for one or more serotype of AAV 
(177, 178). As mentioned above, the genes that are delivered using AAV are expressed 
long-term. Studies in primates (179) and mice (180) have both shown that transferred 
genes are still expressed from 6 months to 1.5 years after injection. Integration into the 
genome is rare and the AAV genes typically exist as multiple copies arranged into 
extrachromosomal concatemers (181). While these viruses lack the specificity of other 
viruses, they are capable of delivering genetic material to a broad range of cells. 
Expression of the delivered gene can be tailored as well. The gene may be expressed in a 
broad range of cells (using the CMV promoter, for instance) or targeted to one particular 
cell type (such as beta cells with the mouse insulin promoter). Several AAV vectors, 
primarily AAV1, AAV2, and AAV8, are currently being tested in a number of human 
phase I, II, and III clinical trials. Many of these are for diseases where a single defective 
protein is responsible for the symptoms of the disease. Specifically, muscular dystrophy, 
cystic fibrosis, Canavan’s disease, and alpha-1-Antitrypsin deficiency (174).   
Part 5: The development and application of the humanized mouse model  
Mutations and Differences in the Lineages of Mice Used in Humanized Mouse 
Models  
History has shown that although mice and non-human primate models are a reasonable 
approximation of overall mammalian biology, they fall short as a specific model for 
predicting human biology. Both have fallen short with disastrous consequences as was 
the case with CD154 blockade. Blocking CD154 is able to prevent the rejection of skin 
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and cardiac allografts in mice (182) as well as pancreatic islet allografts (183). CD154 
blockade was also shown to be effective in non-human primates in extending the survival 
of renal (184) and islet (185) allografts. Both of these animal models identified CD154 
blockade as a promising treatment to prevent the rejection of allogeneic tissues. However, 
the results that were seen in human clinical trials differed greatly from what these models 
predicted and resulted in thromboembolic complications (186). In particular, profound 
differences exist between what has been discovered in the murine system as compared to 
human immunology. Ethical concerns limit what can be studied in humans in vivo, and ex 
vivo studies using human cells are limited in the degree to which they simulate the 
outcomes in vivo. Other models, specifically non-human primate models, have 
traditionally been used as a more accurate system to study both basic biology and to 
predict the outcomes of therapeutics developed for human use. However non-human 
primate models are expensive, require extensive resources, and also have ethical 
concerns. In an effort to avoid these ethical concerns and to also create a better 
representation of the human immune system, several groups have explored 
immunodeficient mouse models as recipients for human tissues (1, 187).  The primary 
requirement in developing a humanized mouse model was creating or identifying strains 
of mice that are deficient in some aspect of the immune response. Such a deficiency was 
first observed in mice bearing a mutation that caused hairlessness, later called nude mice. 
These mice showed impaired development of T cells due to the lack of development of 
the thymus that is caused by a defect in the FOXN1 gene (188). All subsequent models 
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have been built using strains bearing different spontaneous or induced mutations that 
impair the function of the immune system. 
 
Developing a mouse that was truly permissive to engraftment with human cells was 
accomplished over several years through identifying mice with mutations in specific 
genes that would impair immune function and development. First, mutations were 
identified that impaired the development of the adaptive immune system. Early on in this 
search, mutations that impair development of B and T cells were identified. Initially a 
mutation was found that inactivated the Prkdcscid gene, a gene essential for DNA damage 
repair that is required for generation of antigen-specific receptors, and severely impaired 
the development of B and T cells (189-191). Subsequently, mutations in Rag-1 (192) and 
Rag-2 (193), expressing proteins involved in recombination of TCRs and BCRs, were 
found to have a similar phenotype. NSG mice bearing the scid mutation or mutations 
within the Rag-1 or Rag-2 genes, support engraftment with human immune systems but 
overall engraftment levels are low and have limited functionality (194). Targeted 
mutations were also made in the in the IL2rγ, also called the common γ chain, that 
effectively eliminated high affinity signaling for cytokines such as IL2, IL4, IL7, IL9, 
IL15 and IL21 and when combined with scid or Rag mutations, enable efficient 
engraftment of functional human immune systems (195-197). The strain background of 
the immunodeficient recipients will also directly impact the efficiency of human immune 
system development. For example; NOD mice, which develop an autoimmune form of 
diabetes, have a number of genetic advantages that make them more permissive to 
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engraftment with human cells and tissues compared to other mouse strains. Such 
differences include a polymorphism in Sirpα that makes macrophage phagocytosis of 
human cells less likely (198), impaired DC maturation, reduced cytokine production by 
macrophages and reduced NK cell number and function (199). Immunodeficient NOD 
mice have proved to be more permissive to engraftment of human immune systems when 
compared to alternative strains (1). 
Models of the Human Immune system 
Over the years, the many strains of mice that are immunocompromised have been used as 
a host for human cells to study different aspects of human biology. These mice with 
impaired immune responses are all permissive to engraftment with human cells to some 
degree. Of particular interest to the remainder to this thesis is the NOD, Scid, common-
gamma chain knockout (NSG) strain of mouse described above.  Regardless of which 
strain of mouse is used, the models can be broadly divided into three different categories. 
These different models recapitulate all or a specified portion of the human immune 
system (187, 200, 201). Categorically, these models are defined by which types of human 
cells are injected into the mice and the human cell populations that persist long term 
(Figure 4). The Hu-PBL-SCID model is an immunodeficient mouse that is injected with 
human PBMC. This model primarily engrafts with T cells (189, 202). This model is 
simple to establish and mice engraft with both effector and memory T cells but not with 
myeloid cells or B cells. Since the engrafted cells are mature T cells from a human, this 
model allows for the direct study of T cells from donors that have T cell-related 
? ??
disorders. Unfortunately, the PBL-SCID model suffers in that it is difficult to use for 
long-term experiments due to the gradual development of a xenogeneic GVHD.  
 
The human SCID repopulating cell (SRC) mice are generated as newborns through the 
intravenous or intrahepatic injection of CD34+ human cells or the IV injection of adult 
mice. The CD34+ HSC may come from newborn umbilical cord blood, bone marrow 
aspirates, G-CSF mobilized peripheral blood and fetal liver (203). As the mice age, 
multiple lineages of both myeloid and lymphoid cells develop within the mice and 
produce a naïve immune system that contains innate immune cells, B cells, and T cells. 
Although this Hu-SRC SCID model recapitulates most facets of the immune system, the 
T cells are educated on mouse MHC and engraftment levels tend to be low. Finally, BLT 
mice are generated by first surgically implanting human fetal liver and thymus under the 
renal capsule and subsequently injecting human CD34+ cells isolated from the same fetal 
liver used in the surgery (204). These mice, like the SRC-SCID, develop a full naïve 
immune system but the T cells that develop in this model are educated on a human 
thymus as opposed to mouse thymus. The BLT mouse generates HLA restricted T cells 
in addition to more robust T cell engraftment overall and enables development of 
conventional and regulatory T cells.  
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Figure 4: An illustration of the differences between the three main types of 
humanized mouse models 
??
?????
???
???????????
????????????????
????????? ?????
????????????????
????? ??????
????????????????????
??????????
????????????????
???????????
??
????? ??????????????????
???????????
???????????
?? ??
???????????
???????????
???????
?????????????
???????????
???????????
???????
?????????????
? ??
Figure 4: An illustration of the differences between the three main types of 
humanized mouse models  
Approaches to engraft human immune systems into immunodeficient mice (A.) with 
genetic defects in the host immune system are either directly engrafted with human 
cells or undergo a conditioning regimen. One or more of potential cell types are then 
transplanted or injected into these mice. This results in the reconstitution of one or 
more aspects of the human immune system (B.). The engraftment of cells depends 
on which donor cells are used and the resulting humanized mouse is classified as one 
of three different models (C.) that develop distinct cell populations (D.). 
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Hu-SRC-SCID and BLT mice can also be used to generate both B and T cell responses to 
infection. BLT mice infected with EBV (204), HIV (205, 206), and dengue virus (207, 
208) successfully developed virus-specific immune responses.  
 
Although the humanized mouse model is a robust platform with a number of possible 
applications, it has a number of limitations that need to be addressed. Cytokines that are 
produced within the mouse are not always cross-reactive. Human IL-2, for instance, 
binds to both the human and mouse high-affinity IL-2R complex but mouse IL-2 does not 
bind as well to the human IL-2R trimer (209). B cells develop in both the Hu-SRC-SCID 
and the BLT mice but these mice do not develop robust B cell responses to antigen and 
they fail to undergo affinity maturation or isotype switching (210). Mice that have 
mutations in the IL2rγ gene also tend to have poorly defined secondary lymphoid organs 
due to a lack of IL-7 signaling (211).  
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Chapter II – Role of MHC in the engraftment and function of human 
CD8 T cells in NSG Hu-PBL-SCID mice 
 
Introduction 
The NSG Hu-PBL-SCID model is optimized to study mature human T cells within the 
context of a small animal model. To generate Hu-PBL-SCID mice adult human PBMC 
are injected into NSG mice and allowed to expand and fill this mostly empty niche. 
Transiently, innate cells and B cells may be detected, but only CD4 and CD8 T cells 
persist long term. As a result, the NSG mouse will gradually develop a diverse repertoire 
of CD4 and CD8 T cells that reflect what is found in a human donor, allowing 
experiments involving transplantation survival, infection, or models of GVHD. The 
engrafting T cells will mediate a xenogeneic GVHD as the mature human T cells 
recognize mouse xeno-antigens. Previous published work has indicated that CD4 T cells 
are independently capable of engrafting and mediating a similar xenogeneic GVHD but it 
is less clear from the literature whether or not CD8 T cells will behave similarly (212).  
 
Homeostasis and survival of both naïve and memory CD8 T cells in the periphery is 
regulated by several mechanisms, including cytokine signaling and engagement with 
MHC molecules. Several cytokines have been demonstrated to be important factors in 
CD8 T cell survival, with IL-2, IL-7, and IL-15 having essential roles. In addition to 
these cytokines, signaling via CD8 TCR interactions with the MHC-I molecules are 
critical for survival. Normal CD8 T cell function depends on the TCR expressed by the 
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CD8 T cell recognizing foreign antigen that is presented by MHC-I. In addition to being 
necessary for CD8 T cells to function, transient low-level interactions between the TCR 
expressed by the CD8 T cell and MHC-I molecules expressed on other cells is critical for 
cell survival. The Hu-PBL-SCID system will introduce mature T cells into an 
environment where they will be continuously exposed to murine MHC-I, enabling the 
expansion of xeno-reactive human T cells. Previous research has shown that human CD8 
T cells can recognize xenogeneic-antigen expressed by either human or mouse cells 
(213). The engagement of TCR expressed by xeno-reactive CD8 T cells with murine 
MHC will provide a strong activation signal and stimulate a robust immune response to 
the xeno-antigens.  
 
The strong interactions between TCR and xenogeneic-MHC that dominate in the Hu-
PBL-SCID model will likely lead to the activation of CD8 T cells. These mice will also 
lack CD4 Treg cells, which are also an important part of how the immune system 
prevents aberrant activation. Both of these conditions will contribute to the CD8 T cells 
in this model mediating disease in the form of a xenogeneic-GVHD response. 
Observations made in our lab previously indicate that CD4 and CD8 T cells can engraft 
into NSG mice that lack the expression of MHC-I. Since the effector functions of the 
CD8 T cells are tied so closely to the expression of MHC-I, I used two different MHC-I 
deficient NSG strains to answer the question of whether or not CD8 T cells can persist in 
an environment that lacks the expression of MHC-I. I have hypothesized that the 
? ??
engraftment and effector functions will be diminished in MHC-I-deficient mice when 
they are engrafted with human CD8 T cells.  
 
Materials and methods  
 
Mice  
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NOD-scid IL2rγnull, NSG), NSG-B2Mnull, NSG-
(KdDb)null (NSG-KDnull), mice were obtained from colonies maintained by Dr. Leonard 
Shultz at The Jackson Laboratory (Bar Harbor, ME). B6 mice expressing HHD-A2 were 
crossed with NSG-B2Mnull and NSG-KDnull to generate a mouse MHC-I deficient mouse 
that expresses HLA A02*01. All animals were housed in a specific pathogen free facility 
in microisolator cages, given autoclaved food and maintained on acidified autoclaved 
water or sulfamethoxazole-trimethoprim medicated water (Goldline Laboratories, Ft. 
Lauderdale, FL) provided on alternate weeks. All animal procedures were done in 
accordance with the guidelines of the Animal Care and Use Committee of the University 
of Massachusetts Medical School and The Jackson Laboratory and conformed to the 
recommendations in the Guide for the Care and Use of Laboratory Animals (Institute of 
Laboratory Animal Resources, National Research Council, National Academy of 
Sciences, Eighth Edition 2011). 
 
??????????????????
?
? ??
Whole blood was collected from healthy donors into heparin treated 50ml conical tubes. 
Volunteers donated blood under informed consent in accordance with the Declaration of 
Helsinki and approval from the Institutional Review Board of the University of 
Massachusetts Medical School. Following collection, the blood was processed the same 
day by diluting the samples 1:1 with RPMI and overlaying the diluted blood on Ficoll 
density gradient separation media. Following separation, samples were suspended in 
RPMI and either injected directly or separated further using MACS LD or LS columns 
(Miltenyi Biotech). 
 
Cell separation 
 
The PBMCs were either diluted directly for injection or were labeled with magnetic 
beads conjugated to CD4 or CD8 antibodies obtained (Miltenyi biotech, Auburn, CA, 
USA) and used to label a portion of the PBMC cells. CD4 depleted cells, also referred to 
as CD8e cells, were directly labeled with anti-CD4 microbeads and passed over a 
Miltenyi LD column. The fraction that passed through was collected and retained for 
either injection (CD8e groups) or further processed. Purified CD8 T cells (CD8p) were 
obtained by either labeling the CD8 T cells directly or by labeling the CD4 depleted 
CD8e cells with CD8 microbeads and passing them over an LS column. The LS column 
was then flushed with MACS buffer and the bound cells washed and resuspended in 
RPMI media for injection into mice. In some experiments, the CD4+ fraction remaining 
after depleting CD4 cells were relabeled with CD4 microbeads and passed over a LS 
? ??
column to yield a purified CD4 Fraction and an CD4-, CD8- fraction, referred to as the 
flow through cells (FT).   
?
?
Antibodies and flow cytometry 
Human immune cell populations were monitored in mice using monoclonal antibodies 
(mAbs) specific for the following human antigens; CD45 (clone HI30), CD3 (clone 
UCHT1), CD4 (clone RPA-T4), CD8 (clone RPA-T8), CD20 (clone 2H7), CD45RA 
(clone HI100), CD62L (clone DREG-56), HLA-DR (clone G46-6), purchased from 
eBioscience, BD Bioscience (San Jose, CA) or BioLegend (San Diego, CA). Mouse cells 
were identified and excluded from analysis by staining with a mAb specific for murine 
CD45 (clone 30-F11, BD Biosciences). Single-cell suspensions of bone marrow and 
spleen were prepared from engrafted mice, and whole blood was collected in heparin. 
Single cell suspensions of 1x106 cells or 100 μL of whole blood were washed with FACS 
buffer (PBS supplemented with 2% fetal bovine serum (FBS) and 0.02% sodium azide) 
and then pre-incubated with rat anti-mouse FcR11b mAb (clone 2.4G2, BD Biosciences) 
to block binding to mouse Fc receptors. Specific mAbs were then added to the samples 
and incubated for 30 min at 4°C. Stained samples were washed and fixed with 2% 
paraformaldehyde for cell suspensions or treated with BD FACS lysing solution for 
whole blood. At least 50,000 events were acquired on LSRII or FACSCalibur instruments 
(BD Biosciences). Data analysis was performed with FlowJo (Tree Star, Inc., Ashland, 
OR) software. 
 
? ??
Histological analyses 
For histological examination, samples of liver, lung, and small intestine were recovered 
from NSG, NSG-B2Mnull, NSG-KDnull, NSG-B2Mnull/A2, NSG-B2Mnull/HHD-A2, NSG-
KDnull/HHD-A2 mice, immersed overnight in 10% neutral buffered formalin and 
embedded in paraffin. Sections (5 µm) were cut and stained with haematoxylin and eosin. 
Immunohistochemical staining was performed with mAbs specific for human CD45 
(clone 2B11+PD7/26; Dako, Glostrup, Denmark) using a DakoCytomation 
EnVisionDual Link system implemented on a Dako Autostainer Universal Staining 
System (Dako). 
 
GVHD Model 
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Results 
 
CD8 T cells engraft in NSG mice  
 
NSG mice that are injected with human PBMC engraft with both CD4 and CD8 T cells 
(214). These engrafted T cell populations are activated by mouse xeno-antigens, expand 
in number and ultimately mediate a xenogeneic GVHD. However, the mechanisms that 
? ??
enable the survival of human CD8 T cells in NSG mice and the role for CD8 T cells in 
the development of GVHD are not well understood. To elucidate the factors regulating T 
cell engraftment in the Hu-PBL-SCID model, I designed an experimental strategy to 
specifically study CD8 T cells survival in NSG mice. The first question was to determine 
if human CD8 T cells are able to engraft in the absence of other cell populations present 
in PBMC. To do this we first isolated CD8 T cells from the whole fraction of the PBL by 
either positively or negatively selecting the CD8 T cells (Figure 5). The un-manipulated 
PBMC fraction (Figure 5A), the CD4-depleted fraction (CD8e, Figure 5B), and the 
CD8-purified fraction (CD8p), (Figure 5C) were then injected into NSG mice who were 
then monitored for changes in bodyweight and bled bi-weekly to assess engraftment. The 
rationale for using both the CD8e andCD8p fractions was to determine if engraftment of 
human CD8 T cell in NSG mice requires the innate immune cells and/or B cells present 
in the PBMC preparation or if CD8 T cells are sufficient to engraft as a purified 
population. The purity level of each population of cells was confirmed by flow 
cytometry.  
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Figure 5: Purification of different cell fractions from human PBMC 
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Figure 5: Purification of different cell fractions from human PBMC 
Human PBMC were obtained from normal donors and was separated using the 
MACS system. After the whole blood was processed using a Ficoll separation 
gradient, PBMC were retained for injection (A) and a proportion of these cells were 
also labeled with magnetic beads conjugated to an anti-CD4 antibody and passed 
through a depletion column. The cells that passed through the column were 
separated into two groups. The first comprised the CD8e group (B) and the 
remainder was labeled with magnetic beads conjugated to an anti-CD8 antibody 
and isolated using a positive selection column (c).   
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NSG mice were injected IV with whole PBMCs (1x107 cells), CD8e (5 to 6x106 cells), or 
CD8p (2x106 cells). These specific numbers of cells were used to enable the injection of 
similar numbers of CD8 T cells. To assess engraftment of CD8 T cells blood was 
collected at day 14 post-injection, stained with antibodies specific for human T cells, 
including human CD45, CD3, CD4 and CD8 and analyzed the cells by flow cytometry. 
The distinct human populations within the HuPBL-SCID mice were designated using the 
gating strategy shown in the representative flow plots of blood samples from NSG mice 
injected with PBMC (Figure 6). This flow cytometry profile allows human cells 
(CD45+) to be distinguished from the endogenous mouse cells (mCD45+) and identifies 
discrete populations of CD3+ CD4+ and CD3+ CD8+ T cells. As shown in Figure 26C, 
the majority of human cells that engraft in NSG mice injected with PBMC at day 14 are 
human T cells, with both CD4 and CD8 T cells detectable (Figure 26D). Both the PBMC 
injected NSG mice and the CD8e injected NSG mice engrafted with CD45+ cells by day 
14 (Figure 6E). Similar engraftment was not, however, seen in the CD8p-injected group. 
Only low levels of human CD45+ cells were detected in NSG mice injected with CD8p 
fractions. The CD45+ cells detected in all mice at day 14 were predominantly CD3 cells 
(average = 97% CD3+). Overall these data suggest that purified CD8 T cells are unable 
to efficiently engraft in NSG mice and require the presence of one or more non-T cell 
populations to support engraftment.   
??
Figure 6: Blood from mice engrafted with CD8e cells has a detectable human 
population at day 14 
 
0 50K 100K 150K 200K 250K
FSC-A
0
50K
100K
150K
200K
250K
S
S
C
-A
28
0 10
2
10
3
10
4
10
5
<PerCP-Cy5-5/Blue-A>: mLy5
0
10
2
10
3
10
4
10
5
<
A
P
C
-A
>
: 
h
u
C
D
4
5
88.9
2.15
? 
FSC-A 
S
S
C
-A
 
mCD45 
hu
C
D
45
 
88.  
2.15 
C
D
8 
CD4
0 10
2
10
3
10
4
10
5
<Alexa Fluor 700-A>
0
10
2
10
3
10
4
10
5
<
A
P
C
-A
>
98.7
CD3 
C
D
8 
13.6
85.1 
98.7 
PB
MC
CD
8e
CD
8p
0
10
20
30
Day 14
H
um
an
 C
D
45
+ 
C
el
ls
 (%
)
? 
28 
? 
? ? 
? 
P<0.001 
P<0.001 
? ??
Figure 6: Blood from mice engrafted with CD8e cells has a detectable human 
population at day 14 
NSG mice were engrafted with human PBMC, CD8e or CD8p cells and bled at day 
14 to determine if human cells had engrafted. At day 14 blood was drawn from these 
animals and stained as shown in a-d. First, we gated on lymphocytes (A), and within 
this population we used huCD45 and mCD45 to determine the human and mouse 
hematopoietic cells respectively (B). Within the huCD45 population, we determined 
what cells were T cells by CD3 expression (C). Within the CD3 population we 
separated the CD4 and the CD8 T cells (D). At day 14, there was a distinguishable 
population seen in both the PBMC and the CD8e groups but not the CD8p group 
(E). These cells were overwhelmingly CD3+ cells.  
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Engrafted CD8 T cells mediate a GVHD-like response and migrate into the host 
tissues 
 
The data above demonstrated that human CD8 T cells persist in NSG mice injected with 
CD8e cells, which allows the further evaluation human CD8 T cells survival and function 
in NSG mice The ability of the engrafting CD8 T cells to mediate xenogeneic GVHD that 
is seen the Hu-PBL-SCID model was tested. NSG mice were injected IV with human 
PBMC, CD8e and CD8p populations as described above. The bodyweight and overall 
condition of the mice were monitored regularly. NSG mice engrafted with either PBMC 
(Figure 7A) or CD8e cells (Figure 7B) gradually lost weight and developed symptoms 
of xenogeneic GVHD. The NSG mice engrafted with CD8p cells, however, maintained 
their weight throughout the course of the experiment (Figure 7C). Survival of PBMC 
engrafted and CD8e-engrafted NSG mice was significantly reduced compared to CD8p-
engrafted mice (Figure 7D). Human cell chimerism levels were monitored in the 
peripheral blood of engrafted NSG mice bi-weekly by FACS analysis. Levels of 
engraftment at day 14 correlated with the overall mortality. In addition, the activation 
status of the CD8 T cells was evaluated and compared to the initial population of CD8 T 
cells prior to injection. To assess the activation status of the T cells the expression level 
of CD45RA, an isoform of CD45 that decreases after activation, was evaluated by flow 
cytometry. Expression of CD45RA on CD8 T cells was decreased after 14 days in both 
the PBMC and the CD8e groups when compared with the expression on the donor CD8 T 
cells (Figure 7E). This shows that while the CD8 T cells can engraft in NSG mice, CD4 
T cell help may be facilitating CD8 T cell activation and engraftment in the PBMC mice.  
? ??
The CD8p mice were excluded from this analysis as the number of human cells in these 
animals was too low to allow for an accurate comparison (ie fewer than 100 events within 
the CD8 gate). These data show that the CD8 T cells can engraft in NSG mice, they 
develop an activated phenotype, the engrafted cells are functional and mediate a 
xenogeneic GVHD. 
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Figure 7: NSG Mice engrafted with PBMC or CD8e cells have a gradual weight loss 
that corresponds with overall mortality and engraftment with huCD45 
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Figure 7: NSG Mice engrafted with PBMC or CD8e cells have a gradual weight loss 
that corresponds with overall mortality and engraftment with huCD45 
The NSG mice that were engrafted with either PBMC, CD8e, or CD8p cells were 
monitored for signs of weight loss. The PBMC (A) and the CD8e (B) engrafted NSG 
mice gradually lost weight. Similar weight loss was not seen in the CD8p engrafted 
animals (C). This weight loss in the NSG mice correlates with overall mortality (D). 
When we compared the expression of CD45RA on these cells at the time of input to 
the expression at day 14 we saw a dramatic decrease in the PBMC and a more 
moderate decrease in the CD8e group (E).  
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The results above show that human CD8 T cells will engraft in NSG mice and mediate a 
xeno-GVHD. In NSG mice injected with PBMC, CD4 and CD8 T cells infiltrate a 
number of peripheral organs including the mouse liver. To determine if CD8 T cells 
migrate to peripheral tissues in the absence or CD4 T cell help, livers from PBMC 
engrafted and CD8e engrafted NSG mice were recovered when the mice were sacrificed 
(body weight<80% of starting weight or signs of distress) and the tissues were stained 
with H&E to visualize infiltrating leukocytes within these tissues. The liver from an 
unengrafted NSG mouse shows a lack of infiltrates and an overall uniform appearance 
(Figure 8A). The 3 adjacent panels show livers from CD8e-engrafted animals that were 
collected at the time of sacrifice. In all cases, the livers from engrafted NSG mice show 
numerous infiltrates into the liver concentrated near blood vessels (Figure 8B-D) and 
overall alterations to the structure of the organ. This type of infiltration is typical in the 
immunopathology of patients suffering from GVHD with liver involvement (215). In the 
following panels, liver sections from NSG mice that were engrafted with PBMC (Figure 
8 E and H) or CD8e (Figure 8 F and G) were stained with anti-human CD45 to 
visualize infiltrating human cells. These findings indicate that human CD8 T cells are 
able to infiltrate peripheral tissues in NSG mice in the absence of CD4 T cells. 
Collectively, these data together indicate that the engrafted human T cells persist in the 
NSG mice. The CD8 T cells expand within the mice, develop an activated phenotype, 
migrate into peripheral tissues, and mediate a xenogeneic GVHD. Furthermore, the CD8 
T cells are capable of mediating this disease on their own without CD4 T cell help.  
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Figure 8: Liver tissues isolated from CD8e engrafted animals show extensive 
mononuclear infiltrates near vessels 
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Figure 2.4: Liver tissues isolated from CD8e engrafted animals show extensive 
mononuclear infiltrates near vessels  
Liver sections from unengrafted NSG mice (A) or CD8e engrafted mice were 
sectioned and stained with H&E to visualize infiltrating cells (B-D). CD8e-engrafted 
NSG mice had extensive infiltration into the tissues surrounding the blood vessels 
and profound changes in the overall color of the tissues. In the following panels 
Liver sections from NSG mice engrafted with PBMC (E and H) or CD8e (F and G) 
are stained with anti-human CD45 to visualize infiltrating human cells. 
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CD8 T cell engraftment and function depends upon the expression of MHC-I 
  ?
MHC-I has a critical role in maintaining CD8 T cell homeostasis and function (116). To 
examine the contribution of murine MHC to CD8 T cell survival and function in NSG 
mice, I used two different types of MHC-I knockout NSG mice that were developed by 
Dr. Leonard Shultz, at the Jackson Laboratory. The first NSG strain lacks expression of 
the MHC-I locus (NSG-KDnull), and the second stain lacks the B2M molecule necessary 
for surface expression of MHC-I. Previous studies have shown that NSG-B2Mnull mice 
have a delay in the development of xenogeneic-GVHD after injection of human PBMC 
(214). To compare the kinetics of human cell engraftment and of xenogeneic-GVHD 
between the NSG-B2Mnull mice and the NSG KDnull mice, unfractionated PBMC were 
injected IV into NSG, NSG-KDnull and NSG-B2Mnull mice. Injected NSG mice were 
monitored for weight loss, mortality, engraftment, and T cell activation by bleeding these 
animals bi-weekly. As before, all of the animals showed a gradual and progressive weight 
loss (Figure 9A-C) that ultimately lead to the development of GVHD and the euthanasia 
of the mice. The GVHD symptoms were delayed in the NSG-KDnull mice and NSG-
B2Mnull (Figure 9B and C). The delay in weight loss correlated with a delay in the time 
that the animals survived within the parameters of the experiment (Figure 9D). As 
before, all mice that were engrafted with PBMC were engrafted with CD8 T cells at day 
14 and day 28 with a small but not statistically significant trend towards lower 
engraftment in the NSG-KDnull mice (Figure 9E and F).  
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Figure 9: Human PBMC isolated from donors engraft in mice deficient in MHC-I 
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Figure 9: Human PBMC isolated from donors engraft in mice deficient in MHC-I 
PBMC were injected into either NSG, NSG-KDnull, or NSG-B2Mnull mice. All of the 
groups experienced a gradual weight loss with both of the MHC-I deficient strains 
having a trend towards slower weight loss when compared to the NSG mice (A-C). 
The weight loss correlated with the development of GVHD with the NSG-PBMC 
mice developing symptoms noticeably sooner than the NSG-KDnull-PBMC or the 
NSG-B2Mnull -PBMC mice (D). Engraftment was similar among the three groups, 
but there was a noticeable trend towards higher engraftment in the NSG group 
when compared with the MHC-I deficient groups at day 14 and day 28 (E and F).  
 
  
? ??
The data shown above with MHC-I deficient NSG mice indicate that following injection 
with human PBMC, these mice engrafted and develop a xenogeneic-GVHD, although at 
slower kinetics than NSG mice. I hypothesized that enriched CD8 T cells (CD8e) would 
engraft into NSG mice lacking expression of MHC-I but would not mediate a 
xenogeneic-GVHD. Normal NSG mice, NSG-KDnull or NSG-B2Mnull mice were injected 
with 4 to 6x106 enriched CD8 cells. Weights were monitored and the mice were bled bi-
weekly. As before, the CD8e cells caused a gradual and progressive weight loss in the 
NSG mice (Figure 10A). Conversely, NSG-KDnull (Figure 10B) and NSG-B2Mnull mice 
(Figure 10C) did not develop similar weight loss out to 60 days. As expected, this 
resistance to weight loss correlated with an increase in survival. Whereas the majority of 
the NSG mice were sacrificed by day 60, no mice in the NSG-KDnull or the NSG-B2Mnull 
mice (Figure 10D) had developed symptoms of GVHD. Interestingly, although the 
engraftment was reduced, particularly at earlier time points, the CD8 T cells did indeed 
engraft in the MHC-1-deficient mice and the engraftment increased over the course of the 
experiment. At day 14, both the NSG-KDnull and the NSG-B2Mnull had a significantly 
lower proportion of huCD45+ T cells at day 14 (Figure 10E). At day 28 the percentage 
of huCD45 cells was increased in both the NSG-KDnull and the NSG-B2Mnull but they 
both remained significantly lower than the NSG mice (Figure 10F). As before, the 
engrafted cells developed an activated phenotype, expressing less of the CD45RA 
isoform. This difference was most noticeable at day 14 (Figure 10G), but persisted out to 
day 28 (Figure 10H). Overall these data indicate that NSG mice deficient in expression 
? ??
of MHC-I will still support low level engraftment of human CD8 T cells, but these cells 
will not mediate a severe GVHD.  
 
 ?
??
Figure 10: CD8 T cells engraft into MHC-I deficient mice and persist long term 
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Figure 10: CD8 T cells engraft into MHC-I deficient mice and persist long term. 
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Figure 10: CD8 T cells engraft into MHC-I deficient mice and persist long-term. 
NSG, NSG-KDnull, or NSG-B2Mnull mice were injected with either PBMC, or CD8e 
cells. We monitored the mice regularly for weight loss. The NSG mice given CD8e 
cells lost weight (A). The NSG-KDnull (B) and the NSG-B2Mnull (C) mice both 
maintained their bodyweight throughout the course of the experiment. The NSG 
mice engrafted with CD8e cells gradually lost weight and developed symptoms 
consistent with GVHD whereas both the NSG-KDnull and the NSG-B2Mnull mice 
persisted until the end of the experiment with weight loss less than 20% of the 
starting weight (D). The NSG mice engrafted with CD8e cells engrafted with the 
highest level of human cells, followed by the NSG-KDnull mice treated with and the 
NSG-B2Mnull mice at both day 14 (E) and day 28 (F). Finally, CD8e-injected MHC-I 
deficient mice had a population of human CD8 cells that developed an activated 
phenotype at a slower rate than the other groups as defined by a reduction in the 
expression of CD45RA from day 14 (G) to day 28 (H). 
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NSG MHC-I deficient mice permitted CD8 T engraftment but the mice maintained their 
bodyweight long-term and the mice did not develop signs of GVHD. I hypothesized that 
the expression of human MHC-I would restore the ability of the CD8 T cells to mediate 
GVHD. To test this hypothesis, a NSG-KDnull mouse strain expressing human HLA-A02 
in the form of the HHD hybrid protein was used. The NSG KDnull/HHD mouse was 
developed by Dr. Shultz. The HHD molecule is a hybrid protein consisting of HLA 
A0201 expressing a chimeric form of the human MHC-I molecule. Specifically, it is 
made up of the human β2-microglobulin fused to the HLA A0201 α-1 and α-2 domains 
and a murine α-3 domain from H-2Db (216). These mice were injected with 4 to 6x106 
CD8e cells from an HLA-A2-negative donor, weighed regularly, and bled bi-weekly to 
monitor engraftment over the course of the experiment. As expected, NSG-KDnull mice 
engrafted with CD8 T cells maintained their bodyweight throughout the experiment 
(Figure 11A). The NSG-KDnull/HHD mice injected with CD8e cells were again 
susceptible to the progressive weight loss seen in NSG mice (Figure 11B). Following 
injection with CD8e cells, the NSG-KDnull/HHD mice also experienced weight loss at 
rates that were similar to that seen in NSG mice (Figure 11C). As predicted, the 
engraftment levels in the mice expressing transgenic human HLA-A02 was improved 
when compared with MHC-I deficient animals and was closer to what is typically seen in 
NSG mice (Figure 11D). In previous experiments, the MHC-I deficient mice developed 
an activated phenotype slower than the NSG mice, I also decided to evaluate the 
development of an activated phenotype in the NSG-KDnull/HHD mice when compared to 
? ??
the NSG or the NSG-KDnull mice. Blood that was collected at day 21 was stained with 
antibodies to MHC-II (HLA DR) or CD45RO. Expression of CD45RO and HLA DR is 
elevated on antigen-experienced and acutely activated cells, respectively (217, 218). CD8 
T cells recovered from the NSG-KDnull/HHD mice that were injected with CD8e cells had 
significantly higher levels of HLA DR when compared with the NSG-KDnull mice. The 
expression level was similar to that seen in NSG mice that were injected with PBMC 
(Figure 11E). Likewise, CD8 T cells from the NSG-KDnull/HHD mice injected with 
CD8e cells expressed significantly more CD45RO when compared with the NSG-KDnull 
mice. The expression level of CD45RO was similar to that seen in NSG mice that were 
injected with PBMC (Figure 11F). Based on this restoration of susceptibility to GVHD, 
we concluded that the engrafted CD8 T cells were capable of recognizing and interacting 
with the HHD protein and mediating GVHD.  
 
I next tested if the severity of GVHD in NSG NSG-KDnull/HHD mice was altered when 
CD8 cells from HLA-A02+ donors were injected when compared with cells from a HLA-
A02- donor. I hypothesized that CD8 T cells from an HLA-A2+ donor should be tolerant 
to A2-epxressing mouse cells if the primary mechanism of recognition is allo-recognition 
of the A2 molecule. Thus the GVHD severity following injection of CD8 T cells from a 
HLA-A2+ donor is expected to be less severe than the disease mediated by CD8 T cells 
from a A2- individual. To test this PBMC from HLA A02 donors and from non-HLA 
A02 donors were treated as before to generate an enriched population of CD8 cells that 
were used to inject into NSG, NSG-KDnull, or NSG-KDnull/HHD mice.  Mice were 
? ??
injected with 1x107 PBMC or 4 to 6x106 CD8e cells, weighed regularly, and bled bi-
weekly to monitor engraftment over the course of the experiment. Interestingly, we did 
not detect an appreciable difference between the HLA-A02 positive donors and the non-
HLA A02 donors. In both cases there was progressive weight loss and eventual removal 
from the experiment due to weight loss (Figure 11G). Of particular note, the mice that 
were injected with CD8 T cells that were isolated from an HLA A02+ donor did not 
differ significantly from the mice who were injected with CD8 T cells from an HLA 
A02- donor. This indicates both that the CD8 T cells are recognizing the transgenic HLA 
and that the severity of the reaction to the xenogeneic peptides is as severe as the reaction 
to the foreign MHC-I seen in normal NSG mice. 
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Figure 11: Expression of transgenic MHC-I restores mouse susceptibility to GVHD. 
???? ????? ??
???????? 
?
??????? 
?????????? 
? ?
? ? 
KD
nu
ll /H
HD
+P
BM
C
KD
nu
ll /H
HD
+C
D8
KD
nu
ll +C
D8
0
10
20
30
40
50
%
hu
C
D
45
 
Day 14 Engraftment
?????? 
??
Figure 11: Expression of transgenic MHC-I restores mouse susceptibility to GVHD.  
 
P=0.001 
? 
??????
?????? 
? ? 
KD
null
/HHD: A2- 
KD
null
/HHD: A2+ 
KD
null
A2- 
KD
null
 A2+ 
? ??
 
Figure 11: Expression of transgenic MHC-I restores mouse susceptibility to GVHD. 
NSG-KDnull, NSG-KDnull/A2, or NSG mice were injected with CD8e cells from HLA-
A02-negative donors. As seen previously, there were marginal changes in the weight 
of NSG-KDnull (A) mice whereas the expression of HHD (B) restored susceptibility to 
progressive weight loss. The NSG mice expressing HHD had a much higher rate of 
weight loss (C) and that increase in weight loss correlated with an increase in the 
ability of CD8 T cells to engraft in these mice (D). The activation level between the 
NSG-KDnull and the NSG-KDnull-HHD mice was significantly different. These mice 
expressed significantly more CD45RO (E) and more HLA DR (F). When we 
repeated this experiment and compared either A2+ or A2- CD8e cells from donors, 
we saw no significant difference in weight loss, between the NSG-KDnull and the 
NSG-KDnull-HHD mice (G). 
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Discussion 
 
The in vivo survival of mouse CD8 T cells is dependent upon regular low-level 
interactions with the MHC-I molecules expressed on cells (116). In order to determine if 
human CD8 T cells have a similar requirement for survival, proliferation and function, I 
have used the Hu-PBL-SCID model with NSG mice. I used an enriched cell population 
that contains CD8 T cells and engrafted different NSG mouse strains that either express 
murine MHC-I, express no MHC, or express a transgenic human HLA A02*01 complex. 
In the three different instances, I saw profound differences in the engraftment and 
function of the CD8 T cells. Most notably, NSG-KDnull and the NSG-B2Mnull mice had a 
significantly lower proportion of huCD45+ T cells that stayed relatively low throughout 
the course of the experiments, a range of 50-120 days. During this time period, there was 
minimal weight loss and the mice appeared healthy. CD8 T cells were capable of 
persisting, but only at a relatively low level. CD8 T cells engrafting in the NSG-KDnull 
and the NSG-B2Mnull mice developed an activated phenotype, but with significantly 
slower kinetics as compared to NSG mice. Although the human CD8 T cells were able to 
survive in the NSG-KDnull and the NSG-B2Mnull mice, these mice did not develop a xeno-
GVHD. I hypothesize that the NSG-KDnull and the NSG-B2Mnull mice will be useful to 
study the functionality of human T cells in the absence of the confounding effects of 
xeno-GVHD. 
 
Finally, to generate a model of allogeneic GVHD, we crossed the NSG-KDnull mice with 
a strain that expresses a transgenic HLA A02*01 complex that is a hybrid of human and 
? ??
murine proteins. This HHD complex was expressed by the murine cells, restored the 
susceptibility of the mice to GVHD and effectively made a different model of GVHD 
where allogeneic peptides are presented and recognized within the context of the human 
MHC. This model of allogeneic GVHD offers an opportunity to study human GVHD in a 
small animal model where the reactivity of naïve and memory CD8 T cells to foreign 
antigen can be studied and methodologies to reduce or eliminate the reactivity can be 
explored. This is an improvement to the existing NSG model of GVHD because it 
eliminates the inherent reactivity between the human TCR expressed by CD8 T cells and 
the murine MHC-I.  
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Chapter III – Role human cytokines on the engraftment, survival, and 
function of human CD8 T cells 
Introduction: Cellular and cytokine factors that regulate T cell survival and 
function 
?
In Chapter 2, I observed that CD8 T cells engraft into the NSG Hu-PBL-SCID model 
when injected as a part of the whole PBMC or when injected as an enriched population 
lacking CD4 T cells (CD8e cells), but not when injected as a purified population (CD8p). 
Only when CD8 T cells are injected as a purified population (CD8p) do we see that CD8 
T cells generally fail to engraft. The engraftment data with enriched CD8 T cells (CD8e) 
indicated that non-CD4 cells support CD8 T cell engraftment. The engraftment level of 
CD8 T cells was significantly higher for the NSG-PBMC group as compared to NSG 
mice injected with CD8e populations suggesting that CD4 T cells will support CD8 T cell 
engraftment in NSG mice.  
 
The engraftment of purified human CD8 T cells in NSG mice may require help in the 
form of direct cell contact or the production of cytokines. As mentioned above, there are 
a handful of cytokines that are known to be primary factors for T cell survival. In 
particular, IL-2, IL-7 and, to a lesser extent, IL-15 are all important for T cell survival. 
CD4 T cells are also known to be important for CD8 T cell activation and survival, due in 
part to the production of IL-2. Given this information, we decided to test if CD4 T cells 
? ??
could support CD8 T cell engraftment by co-injecting purified CD4 T cells. Since we 
have already observed that CD8e cells will engraft and we know that non-T cells do not 
persist in this model (212, 214), we can presume that the CD8 T cells need only transient 
help from other cells in order to engraft. As we also see that rarely CD8p cells will 
engraft for an unknown reason, I also decided to titrate the dose of CD8p cells to 
determine if there is a threshold number of CD8p cells necessary to engraft.  
  
Materials and methods  
 
Mice 
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NOD-scid IL2rγnull, NSG), and NSG-Tg(huIL7) mice 
were obtained from colonies maintained by Leonard Schultz at The Jackson Laboratory 
(Bar Harbor, ME). All animals were housed in a specific pathogen free facility in 
microisolator cages, given autoclaved food and maintained on acidified autoclaved water 
or sulfamethoxazole-trimethoprim medicated water (Goldline Laboratories, Ft. 
Lauderdale, FL) provided on alternate weeks. All animal procedures were done in 
accordance with the guidelines of the Animal Care and Use Committee of the University 
of Massachusetts Medical School and The Jackson Laboratory and conformed to the 
recommendations in the Guide for the Care and Use of Laboratory Animals (Institute of 
Laboratory Animal Resources, National Research Council, National Academy of 
Sciences, Eighth Edition 2011). 
 
? ??
NSG-huIL7 Tg Mice:  
Administration of recombinant IL7 to HSC-engrafted NSG mice increases human T cell 
responses (219). Using BAC technology, Dr. Leonard Shultz developed NSG-huIL7 Tg 
mice that make physiological levels of human IL7 (1 to 2 pg/ml serum). 
 
Blood preparation 
 
Whole blood was collected from healthy donors into heparin treated 50ml conical tubes. 
Volunteers donated blood under informed consent in accordance with the Declaration of 
Helsinki and approval from the Institutional Review Board of the University of 
Massachusetts Medical School. Following collection, the blood was processed the same 
day by diluting the samples 1:1 with RPMI and overlaying the diluted blood on Ficoll 
density gradient separation media. Following separation, samples were suspended in 
RPMI and either injected directly or separated further using MACS LD or LS columns 
(Miltenyi Biotech). 
 
Cell separation 
 
The PBMCs were either diluted directly for injection or were labeled with magnetic 
beads conjugated to CD4 or CD8 antibodies obtained (Miltenyi biotech, Auburn, CA, 
USA) and used to label a portion of the PBMC cells. CD4 depleted cells, also referred to 
as CD8e cells, were directly labeled with anti-CD4 microbeads and passed over a 
Miltenyi LD column. The fraction that passed through was collected and retained for 
either injection (CD8e groups) or further processed. Purified CD8 T cells (CD8p) were 
? ??
obtained by either labeling the CD8 T cells directly or by labeling the CD4 depleted 
CD8e cells with CD8 microbeads and passing them over an LS column. The LS column 
was then flushed with MACS buffer and the bound cells washed and resuspended in 
RPMI media for injection into Mice. In some experiments, the CD4+ fraction remaining 
after depleting CD4 cells were relabeled with CD4 microbeads and passed over a LS 
column to yield a purified CD4 Fraction and an CD4-, CD8- fraction, referred to as the 
flow through cells(FT).   
 
Antibodies and flow cytometry 
Human immune cell populations were monitored in mice using monoclonal antibodies 
(mAbs) specific for the following human antigens; CD45 (clone HI30), CD3 (clone 
UCHT1), CD4 (clone RPA-T4), CD8 (clone RPA-T8), CD20 (clone 2H7), CD45RA 
(clone HI100), CD62L (clone DREG-56), HLA-DR (clone G46-6), purchased from 
eBioscience, BD Bioscience (San Jose, CA) or BioLegend (San Diego, CA). Mouse cells 
were identified and excluded from analysis by staining with a mAb specific for murine 
CD45 (clone 30-F11, BD Biosciences). Single-cell suspensions of bone marrow and 
spleen were prepared from engrafted mice, and whole blood was collected in heparin. 
Single cell suspensions of 1x106 cells or 100 μL of whole blood were washed with FACS 
buffer (PBS supplemented with 2% fetal bovine serum (FBS) and 0.02% sodium azide) 
and then pre-incubated with rat anti-mouse FcR11b mAb (clone 2.4G2, BD Biosciences) 
to block binding to mouse Fc receptors. Specific mAbs were then added to the samples 
and incubated for 30 min at 4°C. Stained samples were washed and fixed with 2% 
? ??
paraformaldehyde for cell suspensions or treated with BD FACS lysing solution for 
whole blood. At least 50,000 events were acquired on LSRII or FACSCalibur instruments 
(BD Biosciences). Data analysis was performed with FlowJo (Tree Star, Inc., Ashland, 
OR) software. 
 
IL2 
The IL-2 reagent was obtained from Hoffman La Roche and consisted of an IL-2 Fc 
fusion protein.  
 
Results 
Purified human CD8 T cells are dependent upon other cell types to successfully 
engraft  
?
As described in Chapter 2, NSG mice that are injected with purified CD8 T cells (CD8p) 
fail to engraft while those that are injected with CD4 depleted cells (CD8e) engraft with 
CD8 T cells although with slower kinetics when compared to whole human PBMC. 
Given this information, we hypothesized that CD8 T cell engraftment could be supported 
by either the non-T cell fraction, or through help from CD4 T cells that are present in 
whole PBMC-treated mice. Based on this evidence, I devised an experimental scheme 
that isolated human cells into 5 different groups, PBMC, CD8e, CD8p, CD4p, and flow 
through (The remaining CD4- and CD8- cells) (Figure 12).  
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Figure 12: Isolation plan for elucidating the role of other cell types in CD8 T cell 
engraftment 
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Figure 12: Isolation plan for elucidating the role of other cell types in CD8 T cell 
engraftment. 
Beginning with whole PBMC from a healthy donor, some cells were reserved for the 
PBMC group (A) and the rest were labeled with CD4-specific magnetic beads and 
processed with a depletion column. The column was flushed to liberate the bound 
CD4 cells (CD4+) and some of the resulting CD8e cells were retained for injection 
(B). The remaining CD8e cells were labeled with CD8-specific microbeads and 
processed through a purification column. The purified CD8p cells were retained for 
injection (C). The bound CD4+ fraction from the first separation step was retained 
for injection (D). 
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I decided to test whether or not CD4 T cells could provide help to CD8 T cells and assist 
them in engrafting. To conduct this experiment, I isolated CD4p, CD8p and CD8e cells 
from healthy donors.  NSG mice were injected with the CD4p cells (4x106 cells) IV at the 
same time as the CD8p cells (2x106 cells). A separate group of NSG mice were injected 
with CD8p cells alone (2x106 cells) or CD8e cells (5x106 cells). After allowing the cells 
to engraft, mice were bled at 2 weeks and the level of engraftment with human cells was 
analyzed. (Figure 13A) We next decided to test if CD4 T cells that have been lethally 
irradiated could also support engraftment. Lethally irradiated cells will not proliferate but 
they do retain a number of effector functions such as cytokine secretion and limited 
protein synthesis. They may also engage in direct cell interactions with the CD8 T cells. 
To test this, the experiment outlined in (Figure 13A) was repeated with the addition of 
lethally irradiating the CD4 T cells before injecting the cells (Figure 13B).   
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Figure 13: Irradiated and non-irradiated CD4 T cells are capable of supporting the 
engraftment of CD8p T cells into NSG mice 
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Figure 13: Irradiated and non-irradiated CD4 T cells are capable of supporting the 
engraftment of CD8p T cells into NSG mice 
NSG mice were irradiated as previously described and PBMC from healthy donors 
were separated into CD4p, CD8e, and CD8p groups. The CD4p cells were injected 
at a dosage of 4x106 cells per mouse simultaneously with 2x106 CD8p cells. 
Simultaneously, CD8e cells 6x106 or CD8p 2x106 CD8p cells were injected to control 
for engraftment differences. At 2 weeks, the mice were bled to analyze the 
engraftment levels in the blood (A). To determine if transient CD4 help is sufficient 
to support CD8 T cell engraftment, we repeated the experiment as described in part 
(A) but the CD4p cells were lethally irradiated with 2000 rad before injection into 
the NSG mice (B).  
 
  
? ??
Titration of CD8p cells into NSG mice reveals that there is a threshold for 
engraftment 
?
The experiments shown above revealed that injection of 2x106 CD8p cells do not engraft 
without some support from other cell types. The 2x106 CD8 T cell number is similar to 
the amount of CD8s that are injected with 1x107 PBMC, the standard dose in my 
experiments. I next asked the question if there was a threshold for engraftment with this 
cell population. Specifically, I wanted to know if injecting a large amount of CD8 T cells 
would enable engraftment. If CD8 survival is dependent upon a cytokine that is produced 
by CD8 T cells or if there is a rare population of CD8 T cells that can preferentially 
survive, then injecting an increased number of CD8p cells may allow cells to engraft. I 
hypothesized that there would be a certain point at which the number of injected cells 
would become large enough to ensure survival and long-term engraftment of a CD8 T 
cell population that exists long term. To test this, we obtained PBMC from a healthy 
donor and purified the CD8 T cells as described above. Mice were then injected with 
PBMC (10x106 cells/mouse) or CD8p cells at a dose ranging from 1x106 to 8x106 
cells/mouse in an effort to determine if there is a threshold amount that, when injected, 
will result in engraftment. The PBMC group and the highest dose of CD8p cells had an 
increased level of mice removed from the experiment due to their appearance or weight 
loss (Figure 14A). PBMC injected mice engrafted at a high level that was evident by the 
amount of huCD45+ cells seen in the blood at day 21 and day 35 (Figure 14B). Mice that 
were injected with 1x106-2x106 cells had negligible engraftment over the course of 49 
days (Figure 14C-D). Those mice injected with 4x106 cells had a small increase in 
engraftment of CD8 T cells at week 5 and 7 (Figure 14E). Finally, the mice injected with 
? ??
8x106 cells were significantly more engrafted (P<0.01) than all other CD8p groups and 
the rate of removal of these mice from the experiment due to GVHD was not 
significantly different from the PBMC groups. ?
? ?
??
Figure 14: Injecting a large amount of CD8 T cells can overcome the inability of 
CD8p cells to engraft. 
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Figure 14: Injecting a large amount of CD8 T cells can overcome the inability of 
CD8p cells to engraft. 
NSG mice were engrafted with either PBMC or CD8p cells ranging from 1x106 to 
8x106. The bodyweights were measured regularly and the mice monitored for signs 
of GVHD. The survival of the mice is shown in (A) with both the PBMC and the 
8x106 populations showing a marked increase in mortality relative to the other 
groups.  
 
  
? ??
Mice expressing transgenic human IL-7 fail to engraft with purified CD8 T cells 
?
 
As mentioned above, IL-7 is important in the survival of human CD4 and CD8 T cells. 
Given this information, I first tried to support CD8 T cell engraftment by using a system 
that had supplemental IL-7. We obtained NSG mice that express human IL-7 and used 
these mice as recipients for human CD8 T cells. NSG and NSG-TgIL-7 mice were 
injected IV with either PBMC (10x106 cells) or CD8p (2x106 cells). We monitored the 
weight of the animals and noticed the typical decline seen in NSG mice that were 
engrafted with PBMC (Figure 15A) and that decline was the same as what was seen in 
NSG-IL-7 mice (Figure 15B). No such weight loss was seen in either the NSG (Figure 
15A) or the NSG-IL-7 mice (Figure 15B) that were given CD8p cells. Similarly, there 
was no difference in the survival of NSG (Figure 15C) or NSG-IL-7 (Figure 15D) mice 
that were injected with CD8 T cells.  Blood taken from the mice at week 2 indicated that 
there was a detectible population of human cells in both the PBMC NSG and the PBMC 
NSG-IL-7 groups and there was no significant difference between the two groups 
(Figure 15E). Conversely, there was little or no detectible human cells seen in either the 
of the NSG or NSG-IL-7 groups injected with CD8p at week 2 (Figure 15E). The mice 
were bled again at week 4 and there were still no detectable human cells in either of the 
CD8p groups (Figure 15F).  
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Figure 15: Transgenic Expression of IL-7 Fails to Support the Engraftment of 
Human CD8 T Cells 
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Figure 15: Transgenic IL-7 fails to support the engraftment of human CD8 T cells. 
NSG or NSG-IL-7 mice were injected with either PBMC or CD8p cells. Bodyweight 
was regularly monitored for changes. Weights consistently declined in both PBMC 
groups (NSG (A) and the NSG-IL-7 (B)) but did not decline in either of the strains 
injected with CD8p cells. (NSG (A) and the NSG-IL-7 (B)). Blood taken from the 
mice stained with antibodies against CD45 showed a detectible population in the 
PBMC mice, but not the CD8p mice at both week 2 (C) and week 4 (D).  
  
? ??
Exogenous human IL-2 can support the engraftment of purified CD8 T cells  
?
?
Given the ability of a transient population of non-CD8 T cells to support CD8 
engraftment and the result that showed that IL-7 was not sufficient for CD8 engraftment, 
we hypothesized that IL-2 might be capable of supporting CD8 T cell engraftment. To 
test this we injected NSG mice with either CD8e (5 to 6x106 cells) or CD8p (2x106 cells) 
cells isolated as seen above. At the time we injected the human cells, half of the CD8p 
mice were also given a bolus of either PBS, or PBS containing IL-2. Mice were injected 
SC bi-weekly thereafter with either PBS or PBS containing IL-2. Mice were monitored 
regularly for changes in bodyweight (data not shown). Blood was taken at day 14 and 
was stained with antibodies against human CD45, CD3, CD4 and CD8 and analyzed. The 
NSG-CD8e and the NSG-CD8p-IL2 mice had an identifiable population of human cells 
whereas the NSG-CD8p mice had no or negligible human cells (Figure 16A) At day 28, 
we repeated the analysis of the blood and found expansion in all groups but most notably 
in the CD8e and the CD8p+IL-2 groups. (Figure 16B). I sacrificed the mice on day 28 
and compared the number of human cells found in the spleen (Figure 16C) and evaluated 
the CD8 T cells for activation by assessing the prevalence of CD45RA-expressing cells 
(Figure 16D)  
??
Figure 16: Exogenous human IL-2 can support CD8 T cell engraftment 
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Figure 16: Exogenous human IL-2 can support CD8 T cell engraftment  
NSG mice were injected with PBMC, CD8e or CD8p. The NSG-CD8p mice were 
further separated into a PBS and an IL-2 group and were injected bi-weekly with 
either IL-2 or PBS. At 2 and 4 weeks, blood was collected and stained and the 
proportion of human CD45 at week 2 (A) and week 4 (B) showed a significant 
increase in the NSG-CD8p-IL-2 relative to the NSG-CD8p control group. Mice were 
euthanized at week, the number of splenocytes present were counted (C) and the 
splenocytes were stained for markers to identify CD45RA expression on CD8 T cells 
(D).  
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Discussion 
I began these experiments with the goal of determining the role that cell interactions 
specifically CD4 help and cytokine production, has on human CD8 T cell survival and 
function. In the experiments described above, we tested whether CD4 T cell presence, 
higher cell doses of CD8 T cells and cytokines can promote engraftment of human CD8 
T cells in NSG mice. Understanding the factors that regulate and can change CD8 T cell 
homeostasis is important in order to understand how they will behave during infection or 
other immune responses. Understanding of how CD8 T cells will respond to the presence 
or absence of certain stimuli would also be important to help understand why CD8 T cells 
can lose effectiveness during the course of an infection. Additionally, having a small 
animal model where CD8 T cells can be exposed to strong stimuli might also provide a 
platform to test cytokines or drugs that may reverse CD8 exhaustion during chronic 
activation.  
 
Purified CD8 T cells are unable to engraft and survive in NSG mice without the early 
presence of additional cell components, including CD4 T cells. I hypothesized that the 
CD4 T cells, like the non-T cell fraction from the CD8e cells, would be able to support 
CD8 engraftment. In the case of CD4 T cells, it is possible that this help could be in the 
form of direct interaction or through the production of cytokines. Given the results seen 
in our IL-2 experiments, it is possible that the CD4 production of IL-2 may be aiding 
CD8 T cell survival at the critical early stages of engraftment. Interestingly, injections of 
a higher number of CD8 T cells enabled engraftment of the CD8p cells. This suggests 
? ???
that human CD8 T cells could be producing factors that are able to support survival in 
NSG mice but only at a low level. Interestingly, IL-7 did not aid in CD8 T cell survival 
whereas IL-2 did. IL-7 is critical for the survival of naïve CD4 and CD8 T cells whereas 
IL-2 is normally only necessary for the survival of Treg. However, IL-2 can also be 
important for CD8 proliferation especially in the absence of CD4 help (220).  
 
  
? ???
Chapter IV – The regulatory effect of huIL-2 on Treg homeostasis and 
function in NSG BLT mice 
Background on IL-2 and Treg function 
 
The use of recombinant adeno associated virus (rAAV) for in vivo gene delivery is a 
promising approach for the treatment of numerous genetic disorders and as a basic 
research tool (221). AAV is a non-pathogenic, non-envelope parvovirus that infects both 
dividing and non-dividing cells in vivo and supports stable expression of transgenes by 
infected cells (222). An additional advantage for the use of AAV as a gene therapy vector 
is the high level of diversity in AAV-serotypes that enables the targeting of a broad range 
of cell types in vivo (223). AAV-based vectors have been used in mice for the efficient 
delivery and long-term expression of transgenes with positive therapeutic results (224). 
Moreover AAV vectors have shown promise and safety in clinical trials for a number of 
diseases including hemophilia, rheumatoid arthritis, cystic fibrosis, lipoprotein lipase 
deficiency, Leber’s congenital amaurosis, choroideremia, Canavan’s disease, muscular 
dystrophy, alpha-1-antitrypsan deficiency, Parkinson’s disease, macular degeneration and 
heart disease (174). However, the efficient preclinical testing of novel AAV vectors 
expressing transgenes that will act specifically on human cells and tissues is hampered by 
the paucity of appropriate models that recapitulate human biology (225). Previous studies 
using humanized mice have demonstrated the success of AAV vectors for the delivery of 
anti-cancer therapies (226, 227), to express PDX1 in human liver cells (228), to target 
transgene expression to human CD4 T cells (226), and to augment the development and 
? ???
function of human immune systems following CD34+ HSC engraftment (229-232). The 
success of these previous experimental strategies with AAV vectors in humanized mice 
support the use of humanized mouse models to test AAV vectors for gene delivery, 
targeting specific human immune cell populations. 
 
FOXP3+ CD4+ Treg are an essential component of T cell tolerance and physiological 
immune homeostasis (233-235), and IL2 is critical to maintain normal Treg homeostasis 
(236). Low dose IL2 therapies have been tested in both mice and in clinical trials as a 
strategy to increase functional Treg levels and limit autoimmunity and suppress 
transplant rejection (237-240). Low dose IL2 therapies preferentially act through the high 
affinity IL2 receptor that is expressed by Treg (241). Recent studies in NOD mice have 
demonstrated that AAV delivery of IL2 has a protective effect on the development of 
type-1 diabetes (T1D) (237, 238, 242, 243). Injection of NOD mice with an AAV8 vector 
expressing mouse IL2 under the control of the mouse insulin promoter enabled long term 
expression of IL2 by pancreatic beta cells, increased the number of functional Treg and 
delayed progression of T1D (237, 238). Similar effects on Treg levels and delay in 
diabetes progression were also observed in NOD mice injected with recombinant IL2 
(244). Delivery of low dose human IL2 in recent clinical trials has been accomplished by 
repeated injections of recombinant IL2, Proleukin (Aldesleukin) (240). Clinical trials 
have shown that injection of patients with recombinant human IL2 at low doses increases 
human Treg levels and reduces symptoms in uncontrolled chronic GVHD (245), HCV-
induced vasculitis (246), alopecia areata (247) and SLE (248, 249). However, a clinical 
? ???
trial of a rapamycin/IL2 combination therapy in T1D patients resulted in beta cell 
dysfunction (250). T1D patients treated with combination rapamycin and low dose IL2 
showed a significant increase in levels of human Treg but this was accompanied by a 
decrease in C-peptide levels and increases in numbers of NK cells and eosinophils (250). 
Recent studies treating T1D patients with low dose IL2 only have shown efficacy for 
increasing Treg number, but these studies also demonstrated expansion of human NK 
cells and eosinophils in a dose-specific manner (239, 251-253). These findings highlight 
the need for models to test the efficacy of strategies targeting human Treg and the 
development of novel approaches to deliver low dose IL2.  
 
Here we use a humanized mouse model that enables efficient development of functional 
human T cells, including CD4+/CD25+/FOXP3+/CD125dim Treg, to study the 
effectiveness of an AAV vector expressing human IL2. These studies use NOD-scid 
IL2rγnull (NSG) mice engrafted with human fetal thymus and liver tissues, abbreviated as 
the BLT (bone marrow/liver/thymus) model. The BLT model supports robust 
development of HLA-restricted conventional and regulatory T cell subsets (254). Our 
results show that use of an AAV8 vector expressing human IL2 under control of the 
mouse insulin promoter increases the levels of Treg in the blood and spleen of NSG-BLT 
mice. Moreover, the IL2-expanded human Treg cell population maintains the ability to 
suppress immune responses both in vivo and in vitro. Coinciding with the Treg 
expansion, a significant increase in the number and activation status of human NK cells is 
observed, recapitulating the clinical observations. These findings validate that humanized 
? ???
mouse models are effective for the in vivo study of AAV based therapies that specifically 
target human immune cell subsets. 
Materials and methods 
 
Mice 
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NOD-scid IL2rγnull, NSG) mice were obtained from 
colonies maintained by Dr. Leonard Schultz at The Jackson Laboratory (Bar Harbor, 
ME). All animals were housed in a specific pathogen free facility in microisolator cages, 
given autoclaved food and maintained on acidified autoclaved water or 
sulfamethoxazole-trimethoprim medicated water (Goldline Laboratories, Ft. Lauderdale, 
FL) provided on alternate weeks. All animal procedures were done in accordance with 
the guidelines of the Animal Care and Use Committee of the University of Massachusetts 
Medical School and The Jackson Laboratory and conformed to the recommendations in 
the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal 
Resources, National Research Council, National Academy of Sciences, Eighth Edition 
2011). 
 
Fetal tissue transplantation 
Human fetal thymus and fetal liver (gestational age between 16 and 20 week) specimens 
were obtained from Advanced Bioscience Resources (Alameda, CA). Upon receipt, 
tissues were washed with RPMI supplemented with penicillin G (100U/ml), streptomycin 
(100mg/ml), fungizone (0.25 μg/ml), and gentamycin (5μg/ml). The thymus tissue and a 
? ???
portion of the liver were sectioned into 1mm3 fragments for transplantation, as previously 
described (255). The remaining fetal liver was processed to recover human CD34+ 
hematopoietic stem cells (HSC) as described below. Recipient NSG mice were irradiated 
with 200 cGy and implanted with fetal thymus and fetal liver fragments together in the 
renal subcapsular space, as described previously (256). 
 
Enrichment of CD34+ HSC from fetal liver tissue 
To recover human CD34+ HSC, fetal liver was processed as previously described (255). 
Briefly, fetal liver was minced and digested at 37°C for 20 min with a collagenase-
dispase buffer (Liver Digest Medium, Gibco). Recovered cells were washed with RPMI 
supplemented with 10% fetal bovine serum and filtered through a metal sieve. Red blood 
cells were removed by ficoll-hypaque density centrifugation. The fetal liver cells were 
then depleted of CD3+ cells using a magnetic bead negative-selection separation 
technique (Miltenyi Biotec Inc., Auburn, CA), and the percentage of CD34+ cells was 
determined by flow cytometry (CD34 specific antibody, clone 581, BD Biosciences). At 
a minimum of four hours after irradiation, recipient NSG mice were injected IV with 
CD3-depleted fetal liver cells to achieve 1x105 CD34+ HSC per mouse. 
 
ds AAV8 vectors 
The dsAAV vectors were engineered and packaged as previously described (257). 
Briefly, full-length cDNA encoding human IL2 or EGFP were subcloned into a dsAAV 
plasmid (258) containing the murine preproinsulin II promoter (mIP). dsAAV vector 
? ???
packaging was carried out as previously described (238, 259) or produced by the Viral 
Vector Core at the University of Massachusetts Medical School Horae Gene Therapy 
Center (Worcester, MA). Recipient mice were injected IP with 2.5x1011 particles of the 
purified AAV8-huIL-2 or AAV8-EGFP.  
 
ELISA 
Blood was collected from mice into 1,000U of heparin sodium injection, USP (Pfizer 
Injectables, New York, NY) and thoroughly mixed to prevent coagulation. Blood was 
then centrifuged for 30 minutes at 1000xg and the plasma layer collected. Plasma 
samples were then diluted 1:3 in 1% BSA PBS and frozen until levels of IL2 were 
measured. IL2 levels were quantified using a human IL2-specific ELISA kit (BioLegend) 
following the manufacturers protocol. 
 
Antibodies and flow cytometry 
Human immune cell populations were monitored in NSG-BLT mice using monoclonal 
antibodies (mAbs) specific for the following human antigens; CD45 (clone HI30), CD3 
(clone UCHT1), CD4 (clone RPA-T4), CD8 (clone RPA-T8), CD16 (clone 3G8), CD20 
(clone 2H7), CD25 (clones 2A3 and MA-251), CD45RA (clone HI100), CD56 (clone 
NCAM16.2), CD62L (clone DREG-56), CD94 (clone HP-3D9), CD127 (clone A019D5), 
Ki67 (clone B56), FoxP3 (clone 236A/E7), HLA-DR (clone G46-6), NKp46 (clone 
9e2/Nkp46), granzyme B (clone GB11) purchased from eBioscience, BD Bioscience 
(San Jose, CA) or BioLegend (San Diego, CA). Mouse cells were identified and excluded 
? ???
from analysis by staining with a mAb specific for murine CD45 (clone 30-F11, BD 
Biosciences). Single-cell suspensions of bone marrow and spleen were prepared from 
engrafted mice, and whole blood was collected in heparin. Single cell suspensions of 
1x106 cells or 100 μL of whole blood were washed with FACS buffer (PBS 
supplemented with 2% fetal bovine serum (FBS) and 0.02% sodium azide) and then pre-
incubated with rat anti-mouse FcR11b mAb (clone 2.4G2, BD Biosciences) to block 
binding to mouse Fc receptors. Specific mAbs were then added to the samples and 
incubated for 30 min at 4°C. Stained samples were washed and fixed with 2% 
paraformaldehyde for cell suspensions or treated with BD FACS lysing solution for 
whole blood. At least 50,000 events were acquired on LSRII or FACSCalibur instruments 
(BD Biosciences). Data analysis was performed with FlowJo (Tree Star, Inc., Ashland, 
OR) software. 
 
pSTAT5 Staining 
pSTAT5 was stained using the Phosflow staining kit obtained from BD Bioscience (San 
Jose, CA) and following the manufacture’s protocol. Briefly, splenocytes were suspended 
at 5x106 cells/ml in RPMI supplemented with 10% FBS, and 1x106 cells were then added 
to 5mL FACS tubes (BD Biosciences). Splenocytes were then cultured at 37°C/5% CO2 
for 2 hours and either treated with IL2 (50 IU) for 20 minutes at 37°C or left untreated. 
Following the incubation splenocytes were fixed with Cytofix buffer, permeabilized with 
Perm Buffer III, and washed twice in Staining Buffer. Cells were stained at room 
temperature with an antibody specific for pSTAT5 (clone 47/Stat5 (pY694), BD 
? ???
Biosciences) for 60 minutes and then washed with Staining Buffer. Splenocytes were 
then stained with mAbs specific for murine CD45 and human CD4 and CD25. Samples 
were analyzed immediately after staining. 
 
In Vitro Treg Suppression Assay 
Human Treg were tested for the ability to suppress in vitro proliferation of human CD4 T 
cells. CD4 Treg were enriched from AAV8-hu-IL2-treated and PBS-treated NSG-BLT 
mice, and effector CD4 T cells (CD25-) were enriched from a cohort of NSG-BLT mice 
that were generated with tissues not matched to the AAV treated NSG-BLT mice. CD4+ 
T cells were enriched from the spleens of NSG-BLT mice by magnetic bead negative 
selection using a human CD4 T cell isolation kit (Miltenyi Biotech). Enriched CD4+ cells 
were then stained with mAbs to CD25 and CD127, and Treg (CD25+/CD127dim) and 
effector T cells (CD25-) were purified by cell sorting using a BD-FACS ARIA (BD 
Biosciences). Effector T cells were labeled with CFSE (Sigma Aldrich) and incubated for 
5 days with anti-CD3/anti-CD28-coated beads (Miltenyi Biotech) in the presence or 
absence of human Treg at graded ratios. After 5 days, cells were stained with 
fluorochrome-conjugated mAbs and Live/dead viability dye (ThermoFisher) and 
analyzed via FACS for proliferation (CSFE dye dilution). The percentage of proliferation 
inhibition was calculated as previously described by determining the proportion of 
dividing effector T cells from each co-culture as compared to the proportion of dividing 
effectors in the absence of Treg when stimulated with anti-CD3/anti-CD28-coated beads 
(260).  
? ???
 
In Vivo Killing Assay 
NSG-BLT mice and NSG mice not engrafted with human cells were injected IV with 
PBMC (20x106 cells) that were allogeneic to the transplanted tissues in NSG-BLT mice. 
HLA allelic differences between the injected allogeneic PBMC and the BLT-generated 
immune system were used to monitor levels of the injected PBMC. Specifically, PBMC 
from HLA-A2+ or HLA-A3+ donors were injected into BLT mice that were A2- or A3-, 
respectively. Three days after PBMC injection, splenocytes were recovered from the 
injected mice and levels of allogeneic PBMC were determined by staining with mAbs 
specific for either HLA-A2 (Clone BB7.2 BD Bioscience) or HLA-A3 (Clone GAP.A3 
BD Bioscience). For deletion of CD4 T cells, mice were injected IP with 200mg of OKT-
4 (anti-CD4) mAb (BioXcel, Lebanon, NH) on days -8, -7, and -6 before injection with 
allogeneic PBMC. Depletion of CD4 T cells was confirmed by flow cytometry using the 
RPA-T4 clone. 
 
Statistical Analyses 
To compare individual pair-wise groupings, we used one-way ANOVA with Bonferroni 
post-tests and Kruskal-Wallis test with Dunns post-test for parametric and non-parametric 
data, respectively. Results of proliferation assays were analyzed using a T test. For both 
analyses, significant differences were assumed for p values <0.05.  Statistical analyses 
were performed using GraphPad Prism software (version 4.0c, GraphPad, San Diego, 
CA). 
? ???
 
Results 
AAV8-huIL-2 increases the proportion of Treg in BLT mice 
?
 
NSG-BLT mice provide an ideal humanized model to study the effects of human-specific 
therapies on immune system homeostasis and T cell biology. The NSG-BLT model 
supports the growth of human thymus tissue and enables the selection of HLA-restricted 
T cells on autologous human thymic epithelium cells. Representative flow cytometry data 
showing human T cell populations detected in the peripheral blood of NSG-BLT mice at 
12 weeks post implant are shown in (Figure 17A and B). Human CD8+ and CD4+ 
conventional T cells and Treg develop efficiently and populate the periphery of NSG-
BLT mice. Human CD4+ Treg represented an average of 3.6±0.7% of total circulating 
human hematolymphoid cells (human CD45+). The peripheral development of T cell 
subsets suggests that NSG-BLT mice are potential candidates for pre-clinical evaluation 
of immune therapies targeting human T cells. 
 
Previous studies have shown that delivery of IL2 by AAV is an effective approach to 
expand functional Tregs in NOD mice and prevent the development of T1D (238). To 
test the effect of AAV8-delivered huIL2 on human Treg and conventional T cell 
homeostasis, we used the NSG-BLT model. NSG-BLT mice were injected IP with 
2.5x1011 particles of either a human IL2-expressing vector (AAV8-huIL2) or a control 
vector (AAV8-EGFP). Human IL2 was detected in the plasma of NSG-BLT mice 
? ???
injected with AAV8-huIL2 but not in AAV8-EGFP treated mice beginning at 2 weeks 
post injection of AAV (Figure 17C). Human cell chimerism (CD45+) and T cell 
(CD3+/CD4+ and CD3+/CD8+) levels were monitored in the peripheral blood every 2 
weeks over a 10-week time frame. No significant differences were observed in the 
percentages of CD45+ human cells (Figure 17D) and of CD3+ T cells (Figure 17E) 
(both CD4+ and CD8+) in the peripheral blood of NSG-BLT mice injected with AAV8-
huIL2 as compared to control NSG-BLT mice (Figure 17F and 17G). These findings 
suggest that treatment with this AAV vector at this dose establishes constitutive low level 
expression of human IL2, which does not significantly alter human immune system 
homeostasis in NSG-BLT mice. 
  
???
Figure 17: Levels of human CD4 and CD8 T cells are maintained in NSG-BLT mice 
treated with AAV8-huIL2. 
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Figure 17: Levels of human CD4 and CD8 T cells are maintained in NSG-BLT mice 
treated with AAV8-huIL2. 
NSG-BLT mice were generated as described in the Materials and Methods. Human 
immune system development was examined in the blood of NSG-BLT mice 12 weeks 
after implantation of tissues and HSC (A and B). The gating strategy is shown in (A) 
with identification of CD3+ T cells by gating on human CD45+ cells and then gating 
on CD4+ and CD8+ T cells. Within the CD4+ population, Treg were identified as 
CD127low/CD25+/ FoxP3+. Representative human cell engraftment levels are shown 
in (B). The data shown in A and B are representative of 4 experiments. (C) NSG-
BLT mice were injected IP with either AAV8-EGFP or AAV8-huIL2 (2.5x1011 
particles) and human IL2 levels were monitored in the serum by ELISA. Human 
immune system engraftment, including overall engraftment of human CD45+ cells, 
was monitored in the blood of NSG-BLT mice injected with either AAV8-EGFP or 
AAV8-huIL2 (D) CD3+ T cells (E), CD4 T cells (F) and CD8 T cells (G). These 
results are representative of 4 experiments. 
 
 
  
? ???
Table 3: Summary of Treg increase seen in other AAV8-huIL-2 experiments 
?????? ????? ?? ??????? ??????????????? ???
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We next assessed the effect of AAV-huIL2 on human Treg in NSG-BLT mice (Figure 
18). NSG-BLT mice were injected with AAV8-EGFP or AAV-huIL2, and the levels of 
human Treg (human CD3+/CD4+/CD127-/CD25+/FoxP3+) were monitored in the 
peripheral blood every two weeks. Over the course of 10 weeks, the proportion of CD4 
Treg increased significantly in NSG-BLT mice injected with AAV8-huIL2 (Figure 18). 
Representative staining of Tregs from the blood of AAV8-EGFP (Figure 18A) and 
AAV8-huIL2 (Figure 18B) treated NSG-BLT mice shows the changes in the percentage 
of human Treg over time. A significant increase in human CD127-/CD25+ CD4 Tregs 
was detectable at week 4 in NSG-BLT mice after injection with AAV-huIL2, and this 
increase was maintained through week 10 (Figure 18C), as compared to AAV8-EGFP 
injected NSG-BLT mice. The majority of CD127-/CD25+ Treg in both treatment groups 
of NSG-BLT mice were FoxP3+ at all time points, as show by the percentage of CD4 T 
cells that were CD25+/FoxP3+ (Figure 18D) or CD127-/CD25+/FoxP3+ (Figure 18E).  
??
???
Figure 18: Treatment with AAV8-huIL2 increases the percent of human Treg in the 
blood of NSG-BLT mice. 
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Figure 18: Treatment with AAV8-huIL2 increases the percent of human Treg in the 
blood of NSG-BLT mice.  
NSG-BLT mice were generated as described in the Materials and Methods. NSG-
BLT mice were injected IP with either AAV8-EGFP(n=5) or AAV8-huIL2 (n=9) 
(2.5x1011 particles) and bled every 2 weeks to monitor human Treg levels. 
Representative staining (CD127 and CD25) for human Treg over time in NSG BLT 
mice injected with AAV8-EGFP (A) and AAV8-huIL2 (B) are shown. Percent of 
CD4 Treg subsets over time are shown: CD127low/CD25+ (C), CD25+/FoxP3+ (D), 
and CD25+/CD127low/FoxP3+ (E). These results are representative of 4 experiments.  
**p<0.01; ***p<0.001. 
 
 
  
? ???
We devised a gating strategy to identify human Treg in the splenocytes from NSG-BLT 
mice treated with AAV8-EGFP Figures 19A) and AAV8-huIL2 (Figure 19B). 
Significant increases in both the percentages and numbers of human Treg in the spleen at 
the 10-week time point were observed (Figure 19C and 19D). To determine if expression 
of IL2 enhanced human Treg development, we analyzed the CD4+ Treg cell subset 
within the human thymus graft of NSG-BLT mice injected with AAV8-huIL2 (Figure 
19E). The implanted thymus grafts were excised from mice 10 weeks after treatment with 
either AAV8-EGFP or AAV8-huIL-2 and processed to collect thymocytes for analysis by 
flow cytometry. No significant increase in human Treg levels was detected within the 
thymic tissue of NSG-BLT mice treated with AAV8-huIL2. Together these data suggest 
that delivery of human IL-2 by AAV vectors increased the frequency of peripheral 
human Tregs in NSG-BLT mice but did not increase development of Treg within the 
thymus. 
  
???
Figure 19: Treatment with AAV8-huIL2 increases the percent and number of 
human CD4 Treg in the spleen of NSG-BLT mice but does not change levels in the 
thymus. 
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Figure 19: Treatment with AAV8-huIL2 increases the percent and number of 
human CD4 Treg in the spleen of NSG-BLT mice but does not change levels in the 
thymus. 
NSG-BLT mice were generated as described in the Materials and Methods. NSG-
BLT mice were injected IP with either AAV8-EGFP(n=5) or AAV8-huIL2 (n=9) 
(2.5x1011 particles). At 10 weeks post-treatment Treg levels were determined in 
spleens and thymus tissues. The gating strategy used for analyzing splenocytes is 
shown for NSG-BLT mice treated with AAV8-EGFP (A) and AAV8-huIL2 (B). The 
proportion (C) and numbers (D) of CD127low/CD25+/FoxP3+ Tregs are shown. The 
human thymic tissue was recovered from NSG-BLT mice injected with either 
AAV8-huIL2 or AAV8-EGFP, and the proportion of CD4 Treg was determined (E). 
These results are representative of 4 experiments. ***p<0.001. 
 
  
? ???
Expression of human IL2 in NSG-BLT mice stimulated a significant increase in the 
levels of peripheral human Treg. To assess their phenotype, we first examined Treg 
expression of CD45RA and CD62L in AAV8-treated NSG-BLT mice. 
CD45RA+/CD62L+ human Treg are capable of robust expansion and efficiently suppress 
immune responses (261). The levels of CD45RA+/CD62L+ human Treg were 
significantly higher in blood (Figure 20A) and spleen (Figure 20B) of AAV8-huIL2-
treated NSG-BLT mice as compared with Treg from AAV8-EGFP-treated NSG-BLT 
mice. AAV8-huIL2-treated NSG-BLT mice also had a higher proportion of Ki67+ human 
Treg in the spleen when compared to the AAV8-EGFP-treated NSG-BLT mice (Figure 
20C). A higher proportion of Ki67+ human Treg was also detected in the blood of 
AAV8-huIL2-treated mice but this difference did not reach statistical significance (data 
not shown). Expression of CD25 (IL2 receptor alpha chain) was increased on human 
Treg in the blood of NSG-BLT mice 2 weeks after treatment with AAV8-huIL2, and 
increased CD25 expression was maintained through the 10 week experiment (Figure 
20D).  
 
To test responsiveness of human Treg to IL2 stimulation we assessed levels of 
phosphorylated STAT5 (pSTAT5) after exposure to IL2 in vitro. Splenocytes from NSG-
BLT mice injected 10 weeks previously with either AAV8-huIL2 or AAV8-EGFP were 
stimulated in vitro with recombinant huIL2 for 20 minutes and evaluated for pSTAT5 
expression by flow cytometry. CD4 Treg were identified as CD3+/CD4+/CD25+ cells 
(Figure 20E). Within this population we quantified the mean fluorescent intensity (MFI) 
? ???
of pSTAT5 staining. Tregs from NSG-BLT mice injected with AAV8-huIL2 or AAV8-
EGFP showed a similar increased level STAT5 phosphorylation in response to IL-2 
stimulation when compared to one another (Figure 20F). These results demonstrated that 
human Tregs exposed to chronic IL-2 stimulation maintain responsiveness to IL-2. 
  
???
Figure 20: AAV8-huIL2 treatment alters the phenotype and homeostasis of human 
Treg in NSG-BLT. 
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Figure 20: AAV8-huIL2 treatment alters the phenotype and homeostasis of human 
Treg in NSG-BLT. 
NSG-BLT mice were generated as described in the Materials and Methods and were 
injected IP with (2.5x1011 particles) of either AAV8-huIL2 (n=9) or control AAV8-
EGFP(n=5)  Expression of phenotypic and proliferation markers by the recovered 
human Treg was determined at 10 weeks post-treatment. The frequency of human 
Treg co-expressing CD45RA and CD62L was determined in blood (A) and spleen 
(B). To determine the proportion of human Treg undergoing cell division, 
expression of Ki67 by splenic Treg was evaluated (C). Expression of CD25 by Tregs 
that were recovered from the blood of NSG-BLT mice was evaluated every 2 weeks 
after AAV treatment (D). The data shown in A-D are representative of 4 
experiments. STAT5 phosphorylation (pSTAT) was evaluated in Treg recovered 
from the spleen of NSG-BLT mice 10 weeks after AAV treatment (E and F). 
Splenocytes were stimulated with 50 IU of recombinant human IL-2 for 20 minutes 
or unstimulated (medium only) and then pSTAT5 levels were evaluated by flow 
cytometry. The gating strategy (E) and the pSTAT5 levels detected in 
CD3+/CD4+/CD25+ cells (F) are shown. The data shown in E and F are 
representative of 2 experiments.  **p<0.01; ***p<0.001; ****p<0.0001. 
  
? ???
Treg isolated from AAV8-huIL-2 treated animals are responsive to stimuli and 
functional 
?
 
Human Treg from AAV8-huIL2 treated NSG-BLT mice maintain functionality.  
The results presented above show that expression of human IL2 by an AAV vector 
increases the levels of Treg in NSG-BLT mice but does not indicate whether the Treg 
population maintains overall functionality in vitro and in vivo. For in vitro suppression 
assays, human Treg (CD4+/CD127low/CD25+) were sorted from the spleens of AAV8-
EGFP or AAV8-IL2-injected NSG-BLT mice 5 weeks after treatment. Splenic effector 
human T cells (CD4+/CD25-) were enriched from a separate cohort of otherwise 
untreated NSG-BLT mice (allogeneic donor). The two recovered populations were then 
used in a CFSE-based proliferation suppression assay (260). CFSE-labeled, effector 
CD4+ T cells were stimulated with CD3 and CD28 in the presence or absence of graded 
numbers of purified human Treg. After 5 days of in vitro culture, proliferation of the 
CD4+ conventional T cells was assessed by dilution of CFSE. Human Tregs recovered 
from NSG-BLT mice injected with AAV8-huIL2 or AAV8-EGFP were able to suppress 
CD4 proliferation and this effect decreased with lower Treg:T effector ratios (Figure 
21A). No statistical differences in suppression were observed between Treg recovered 
from AAV8-huIL2 or AAV8-EGFP treated mice. These results indicate that human Treg 
responding to IL-2 in NSG-BLT mice maintain in vitro functionality. 
 
To assess their in vivo function, PBMC from a donor that was HLA-mismatched with the 
BLT tissue donor were injected into non-engrafted NSG mice or into NSG-BLT mice 
? ???
treated with either AAV8-EGFP or AAV8-huIL2. Specifically, allogeneic donors that 
were mismatched at HLA-A2 or A3 were identified, as this enabled the direct monitoring 
of A2+ or A3+ allogeneic PBMC in the NSG-BLT mice by flow cytometric analysis. 
Three days after injection of PBMC, the levels of HLA-mismatched PBMC recovered 
from the spleens of recipient mice were determined. NSG-BLT mice treated with AAV8-
EGFP had significantly lower levels of mismatched PBMC as compared to the non-
engrafted NSG mice (NSG Control), indicating that the BLT immune system efficiently 
rejected the injected allogeneic human cells (Figure 21B). In contrast NSG-BLT mice 
treated with AAV8-huIL2 showed a significant increase in detectable HLA-mismatched 
PBMC as compared to the AAV8-EGFP group (Figure 21B). These results indicate that 
treatment with AAV8-huIL2 suppressed the ability of BLT mice to reject allogeneic 
human PBMC.   
 
To determine whether this suppressive effect was due to CD4+ T cells, we injected HLA-
mismatched PBMC into non-engrafted NSG mice (NSG Control) or AAV8-treated NSG-
BLT mice that were depleted of CD4+ cells 5 days prior to injection of allogeneic 
PBMC. Injection of AAV8-EGFP-treated NSG mice with a CD4-depleting antibody prior 
to injection of PBMC did not reduce the number of injected PBMC detected in the spleen 
of these mice (Figure 21C). Consistent with the results shown in Figure 21B, NSG-BLT 
mice treated with AAV8-huIL2 had a significant increase in the detectable levels of 
HLA-mismatched PBMC as compared to the AAV8-EGFP treated group. However, 
depletion of CD4+ cells from NSG-BLT mice treated with AAV8-huIL2 resulted in a 
? ???
significant reduction in detectable HLA-mismatched PBMC as compared to the AAV8-
huIL2 group that was not CD4-depleted (Figure 21C). The results from the CD4 
depletion experiments indicate that the suppression of allo-specific immune responses in 
NSG-BLT mice treated with AAV8-huIL2 requires a CD4+ T cell population. Together 
these results demonstrate that AAV delivery of human IL2 stimulates an increase in 
functional human CD4+ (Treg) in NSG-BLT mice. 
  
???
Figure 21: Human Tregs from AAV8-huIL2 treated NSG-BLT mice function in 
vitro and in vivo. 
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 Figure 21: Human Tregs from AAV8-huIL2 treated NSG-BLT mice function in 
vitro and in vivo.   
The ability of human Treg in NSG-BLT mice treated with AAV8-huIL2 to suppress 
human effector T cell responses was elevated with in vitro (A) and in vivo (B and C) 
assays. NSG-BLT mice were generated as described in the Materials and Methods, 
and were injected IP with 2.5x1011 particles of AAV8-EGFP or AAV8-huIL2. (A) 
Splenic human Treg (CD4+/CD127low/CD25+) were sorted from AAV8-EGFP or 
AAV8-IL-2 treated NSG-BLT mice 5 weeks after treatment. Splenic effector human 
T cells (CD4+/CD25-) were enriched from a separate cohort of NSG-BLT mice 
(allogeneic donor). The effector CD4 T cells were labeled with CFSE, cultured with 
the purified human Treg at the indicated ratios and stimulated with CD3/CD28 
coated beads for 4 days. The percent inhibition was calculated as described in the 
Material and Methods. The data shown are an average of 3 independent 
experiments. (B) Human PBMC (15x106) were injected into either non-engrafted 
NSG mice and NSG-BLT mice treated 4 weeks earlier with either AAV8-EGFP or 
AAV8-huIL2 (2.5x1011 particles). The PBMC were from a donor that was HLA-
mismatched (allogeneic) to the engrafted BLT immune system. Specifically, HLA-
A2 and A3 mismatched donors were used. Three days after injection of allogeneic 
PBMC, splenocytes were recovered and the levels of injected PBMC were 
determined in the peripheral blood by flow cytometry staining with antibodies to 
HLA-A2 or HLA-A3 to identify A2+/A3+ donor PBMC. The total number of 
recovered donor PBMC was then determined. (C) To determine if CD4 T (Treg) 
? ???
suppressed the killing of allogeneic PBMC in NSG-BLT mice treated with AAV8 
huIL-2, allogeneic donor PBMC were injected into non-engrafted NSG mice and 
NSG mice treated 4 weeks earlier with either AAV8-EGFP or AAV8-huIL2 as 
described in B. In addition, mice in the indicated groups were treated with an 
isotype control antibody or an antibody against human CD4 to deplete CD4 T cells 
(including Treg) from the BLT immune system 5 days before injection of donor 
PBMC. Three days after injection of allogeneic PBMC, splenocytes were recovered 
and the levels of injected PBMC were determined in the peripheral blood by 
staining with antibodies to HLA-A2 or A3. The total numbers of recovered donor 
PBMC were then determined. The data shown for B and C are representative of 2 
independent experiments. *p<0.05; **p<0.01; ****p<0.0001 
 
  
? ???
AAV8-huIL2 treatment does not alter the proportion of conventional CD4 or CD8 T 
cells in NSG-BLT mice.  
?
?
Conventional human effector and memory CD4 and CD8 T cells constitutively express 
the IL2 receptor beta (CD122) and common gamma γ (CD132) chains that enable 
intermediate IL2 binding and signaling. Moreover acutely activated conventional T cells 
will also upregulate expression of CD25 (IL2 receptor alpha chain), creating a high 
affinity IL2 receptor (262). To determine if treatment with AAV8-huIL2 stimulates 
activation of human T cells in NSG-BLT mice, we first evaluated the phenotype and 
activation status of conventional CD4 and CD8 T cells. At 10 weeks post treatment with 
AAV8 vectors, CD4 and CD8 T cells from the peripheral blood of NSG-BLT mice were 
evaluated for expression of HLA-DR as a marker of acute activation and for the presence 
of naïve cells (CD45RA+/CD62L+), effector/memory cells (CD45RA-/CD62L-) and 
central memory human CD45RA-/CD62L+ T cells. Consistent with the increased 
function of human Treg, the percent of conventional CD4 and CD8 T cells expressing 
HLA-DR in NSG-BLT mice treated with AAV8-huIL2 was significantly lower as 
compared to control NSG-BLT mice (Figure 22A and 22E). However, no significant 
differences were observed in the percentages of naïve, effector/memory and central 
memory CD4 (Figure 22B-D) and CD8 (Figure 22F-H) T cells. These data indicate that 
AAV8-huIL2 treatment slightly reduces the levels of acutely activated CD4 and CD8 T 
cells but does not significantly alter the subset distribution of the conventional T cell 
populations. 
  
???
Figure 22: Conventional human T cells from AAV8 EGFP-treated and AAV8-huIL2 
treated NSG-BLT mice have a similar phenotype. 
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Figure 22: Conventional human T cells from AAV8 EGFP-treated and AAV8-huIL2 
treated NSG-BLT mice have a similar phenotype.  
NSG-BLT mice were generated as described in the Materials and Methods and were 
injected IP with either 2.5x1011 particles of AAV8-EGFP(n=5) or AAV8-huIL2 
(n=9). At 10 weeks post-treatment, conventional human CD4 (A-D) and CD8 (E-H) 
T cells from the blood were evaluated for the expression of HLA-DR (A and E), and 
for CD45RA and CD62L to determine the proportion of naïve (CD45RA+/CD62L+) 
(B and F), effector/effector memory (CD45RA-/CD62L-) (C and G), and central 
memory (CD45RA-/CD62L+) (D and H). These results are representative of 4 
experiments. *p<0.05; **p<0.01.  
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AAV8-huIL-2 treatment increases the number of NK cells recovered from the 
spleen 
 
Human NK cells defined as NKp46+/CD94High/Low constitutively express the low affinity 
IL-2 receptor complex and will proliferate in response to treatment with IL-2 (238). We 
next evaluated NK numbers and activation in AAV8-EGFP and AAV8-huIL2 treated 
NSG-BLT mice. Representative flow panels of NK cells in the spleen at 10 weeks are 
shown in Figure 23A. NSG-BLT mice treated with AAV8-huIL2 had significantly 
higher percentages and numbers of human NK cells in the spleen as compared to AAV8-
EGFP-treated NSG-BLT mice (Figures 23B-C). Treatment with AAV8-huIL2 also 
resulted in a significant increase in the number of NK cells that expressed granzyme B, 
which identifies NK cells that have cytotoxic activity (Figure 23D).  Overall these data 
demonstrate the treatment with AAV8-huIL2 results in a significant increase in NK cell 
numbers and their activation status. 
 
  
???
Figure 23: AAV8 huIL-2 treatment increases the number and activates human NK 
cells in NSG-BLT mice. 
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Figure 23: AAV8 huIL-2 treatment increases the number and activates human NK 
cells in NSG-BLT mice. 
NSG-BLT mice were generated as described in the Materials and Methods and were 
injected IP with either 2.5x1011 particles of AAV8-EGFP (n=5) or AAV8-huIL2 
(n=9). At 10 weeks post-treatment NK splenic cell numbers and activation status 
were determined. The gating strategy used for analyzing splenocytes is shown for 
NSG-BLT mice treated with AAV8-EGFP (A) and AAV8-huIL2 (B). Human NK 
cells were defined as NKp46+/CD94+/CD56+. The total numbers of human NK cells 
recovered from spleens of NSG-BLT mice are shown (C). The proportion of human 
NK cells expressing granzyme B is shown (D). These results are representative of 4 
experiments. **p<0.01. 
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Discussion 
Gene therapy is an exciting new therapy that has the potential to address several diseases 
that are, as of yet, untreatable or require lifelong treatments that are expensive and 
invasive. Despite the possible applications, there are potential problems that can and have 
arisen when these therapies have been directly tested in humans. Furthermore, current 
animal models fall short of being able to predict human-specific outcomes and there is an 
urgent need to devise a way to test these therapies in a pre-clinical in vivo model (263). 
One approach to address this need has been the development of a humanized mouse 
model of the immune system. Several groups have worked to create a strain of mouse that 
is permissive to engraftment with human cells and to develop  reliable methods to 
replicate the human immune system (187, 264, 265). Using such a model, we have tested 
the systemic implications of delivering human IL-2. Our experiments have shown that 
IL-2 delivered via an AAV vector to a humanized mouse model reproduces the effects of 
low dose IL2 therapies on human immune system homeostasis that were observed in 
clinical trials (266).  
 
In these experiments, we used the NSG-BLT mouse model because it develops a 
consistent population of both conventional and regulatory T cells that are educated on 
human HLA in the human thymic organoid present in this model (204, 267, 268). Over 
the course of our experiments, we have demonstrated that the AAV vector caused a 
systemic elevation of the human IL-2 levels and that this elevation results in an increase 
in the number of functional human Treg within the BLT mice. Although there is a 
? ???
dramatic impact on the Treg, this treatment  has minor effects on conventional T cell 
numbers and function. However, a concurrent increase in the numbers and activation of 
human NK cells was evident in NSG-BLT mice treated with AAV8-huIL2. These results 
support the utilization of the BLT model to study therapies targeting human Treg and 
indicates that BLT mice are effective tools to study the impact of AAV therapies on 
human immune system function and homeostasis.  
 
 
A major breakthrough for the in vivo study of human immune systems followed the 
development in the mid-2000’s of immunodeficient mice with a mutation in the 
interleukin-2 (IL-2) receptor γ-chain locus (Il2rg; also known as γc and CD132) (269-
272). The targeted mutation of Il2rg completely prevents murine natural killer (NK) cell 
development, and cripples host innate immune function. The NSG strain has become the 
most widely used immunodeficient mouse strain for the engraftment of human cells and 
tissues worldwide (273). NSG mice support engraftment with human HSC and immune 
system development (274-276) due, in part, to expression of a signal regulatory protein 
alpha (Sirpa) allele that has a close homology to human SIRPA (277). The NSG mouse 
also supports the implantation of human fetal thymic and liver tissues for the generation 
of BLT (Thy/Liv) mice (255, 278). The robust development of human immune systems 
in NSG-BLT mice has enabled the study of numerous aspects of human immunity 
including; 1) infectious diseases with pathogens such as John Cunningham virus (JCV), 
chlamydia, dengue virus, EBV, ebola virus, HIV, Kaposi’s sarcoma-associated virus, and 
mycobacterium, 2) immune responses to immunization with viral glycoproteins, and 3) 
? ???
immune responses to tissue allografts (201, 265, 279-285). An important advantage of the 
BLT model is the growth of human thymic tissues engrafted with autologous human HSC 
that enables education of human conventional and regulatory T cells on human thymic 
epithelium and the development of HLA-restricted T cells (254). Moreover the human 
Tregs that develop in BLT mice are functional, making this model attractive to study the 
impact of immune therapies on HLA-restricted Treg function and homeostasis (286, 
287). Our findings with IL2 treatment of NSG-BLT mice reproduce observations from 
clinical trials showing that low dose IL2 therapies increase functional Treg and NK cells 
in patients (239, 288) and validate the use of the NSG-BLT model as a platform to test 
approaches targeting human Treg. 
 
Low dose IL2 therapies increase levels of functional Treg in humans but also have the 
potential to stimulate immune cell populations that may be detrimental to the patient 
including NK cells, eosinophils and memory T cells (240). Humanized mouse models 
have been used to study the role of IL2 in human immune system homeostasis. Ito and 
colleagues developed a NOD/Shi-scid-IL2Rγnull (NOG) mouse strain expressing a human 
IL2 transgene (NOG-IL2) (289). Human HSC-engrafted NOG-IL2 mice showed a 
significant increase in functional human NK cells as compared to NOG mice but no 
effect on human T cells was reported. The NOD-IL2 transgenic mice also support 
enhanced engraftment of human CD8 T cells purified from peripheral blood and the 
engrafted CD8 T cells mediated a severe xeno-GVHD (290). A previous study also 
demonstrated that hydrodynamic delivery of a plasmid expressing human IL2 into NSG 
? ???
mice enhanced survival of in vitro expanded human Treg (291). However hydrodynamic 
injection of the IL2 expressing plasmid in NSG mice engrafted with PBMC also 
accelerated the development of xenogeneic GVHD. A recent study examined the impact 
of treating humanized NSG mice with IL2-antibody complexes, which in standard 
immunocompetent mouse models alters T cell and NK cell homeostasis (292). NSG mice 
expressing human HLA-A2 and engrafted with A2+ HSC from UCB were challenged 
with a human melanoma cell line and then treated with human IL2-antibody complexes 
(Hu-IL2c). One Hu-IL2c tested did not significantly alter the frequencies of human 
conventional CD4 and CD8 T cells but did stimulate an increase in T-bet positive, 
effector T cells and an increase in human Treg. Our studies show that IL2 delivered by 
AAV stimulates a significant increase in Treg and NK cells in NSG-BLT mice but does 
not dramatically alter the frequency or phenotype of conventional T cells. Moreover the 
Treg increased AAV-huIL2 cells maintained functionality. Studies are currently 
underway to determine the functionality of NK cells recovered from NSG-BLT mice 
treated with AAV-huIL2. 
 
The significant increase of functional human NK cells in NSG-BLT mice injected with 
AAV8-IL2 and in clinical trials with low dose IL2 therapies (240) highlights the ability 
of human NK cells to respond to low levels of human IL2. IL2 binding and signaling is 
mediated by expression of three distinct receptor subunits including CD25 (IL2Rα), 
CD122 (IL2Rβ) and CD132 (IL2Rγ) in varying combinations on the cell surface (293). 
The high affinity IL2 receptor (IL2R), which is constitutively expressed on CD4+ 
? ???
FOXP3+ Treg, is a heterotrimer comprised of the 3 subunits (CD25, CD122, and CD132) 
(294). The majority of NK cells express the intermediate-affinity receptor, a dimeric 
IL2R that consists of CD122 and CD132, which are the signaling subunits of the 
receptor, and are thought to respond to only high levels of IL2 (295). A small population 
of CD56-bright human NK cells express CD25 and respond efficiently to low dose of 
IL2, suggesting that these may be the NK cell subset that expands in vivo with low dose 
IL2 therapies (296). A recent study has also shown that trans-presentation of IL2 bound 
to CD25 activates CD25-negative NK cells (297), suggesting an additional mechanism 
for activation of NK cells by low dose IL2 therapies. The generation of novel IL2 
therapies that selectively target Treg but do not activate NK cells may be possible using 
IL2 specific antibodies (298) or by the development of modified IL2 molecules (299). 
Regardless of the approach, the NSG-BLT mouse model will be an effective tool to 
assess the efficacy of new IL2 strategies.  
 
Overall our study highlights the utility of humanized mice engrafted with human immune 
systems in validating AAV vectors expressing immune modulatory therapies. NSG-BLT 
mice treated with AAV8-IL2 displayed the expected results on human immune system 
homeostasis that were observed in clinical trials. These results support the use of the 
NSG-BLT model to study more targeted approaches to IL2 therapy that avoid the 
activation of NK cell populations while still inducing a more tolerogenic environment 
through selectively increasing the Treg population. Humanized mice present a convenient 
and safe pre-clinical system for testing such novel therapies before they are used in 
? ???
human clinical trials. More importantly, NSG-BLT mice are more likely to yield results 
that are relevant to human physiology than testing in comparable immunocompetent 
small animal models given the significant differences between human and mouse 
immunobiology (300, 301). 
?  
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Chapter V – Discussion 
 
Delineating the role of HLA and cytokines in the survival and function of CD8 T 
cells 
CD8 T cells are an important part of the immune system that is vital for the control of 
viruses, intracellular pathogens and cancer. The absence of CD8 T cells, in many cases, 
can lead to chronic viral infection instead of viral clearance as seen in HCV (302). In 
other circumstances, CD8 T cells may activate in response to a viral infection but fail to 
maintain the response necessary to clear the virus as is seen in people who develop 
chronic infection with HCV versus those who clear the infection (303). Chronic infection 
may also cause CD8 T cells to exist in a state of constant stimulation which can lead to T 
cell exhaustion and further impairment in the ability to mediate effector functions (304, 
305). Because CD8 T cells are so important for the immune response, it is crucial to 
understand how abnormal conditions may change the ability of CD8 T cells to respond to 
infection. The Hu-PBL-SCID model discussed above represents an environment where 
CD8 T cells will persist long term and where they can be exposed  artificial conditions. 
This could be constant stimulation that would mimic that seen in chronic infection or 
inflammation. After exposure to conditions that may similarly alter CD8 effector 
functions, such as driving the cells towards exhaustion, the CD8 T cells can be treated 
with cytokines or candidate drugs to evaluate what treatments will return the CD8 T cells 
to a responsive state.  
 
? ???
In this research, I have undertaken an in depth investigation of both the survival 
requirements and factors required for efficient T cell function in two different in vivo 
mouse models. First, I used a variety of MHC-I deficient mice in an attempt to ascertain 
what elements are crucial for both survival and function of human CD8 T cells. Our 
initial hypothesis that the expression of MHC-I was essential for function and for 
efficient engraftment of CD8 T cells was demonstrated by comparing the engraftment, 
the proliferation and the function of CD8 T cells in normal NSG mice with that of MHC-I 
deficient NSG mice. IL-7 had no apparent effect on the engraftment of the purified CD8 
T cell population. Given the importance of IL-7 in the normal homeostatic survival of T 
cells, I anticipated that the transgenic NSG-IL-7 mice would better support T cell 
engraftment especially as the phenotype of the engrafted cells is overwhelmingly naïve 
and IL-7 is crucial for the survival of naïve T cells. When CD8 T cells are exposed to 
TCR-MHC-I interactions in the presence of IL-2 they can undergo bystander activation 
(306). This causes a shift to a more activated phenotype and strong proliferation. Given 
the results we have seen here; it is likely that the ability of IL-2 but not IL-7 to facilitate 
engraftment is due largely to this phenomenon. As this would also accelerate the course 
of the xenogeneic-GVHD, it would also function in a feed-forward manner and kindle the 
CD8 response to the mouse MHC-I, which in turn would result in more cytokine 
production and activation.  
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Implications of this research and general conclusions  
The role of HLA/MHC-I in the survival and function of CD8 T cells 
 
CD8 T cell survival, proliferation and function is linked with and to a degree dependent 
upon continuous interaction with MHC-I. In my experiments using NSG mice that are 
engrafted with either CD4 and CD8 T cells (PBMC) or enriched CD8 T cells (CD8p) I 
was able to show that the efficient development of xenogeneic GVHD is in part 
dependent upon the presence of murine MHC-I. While this result was not, by itself, 
surprising, the persistence of CD8 T cells in the MHC-I deficient NSG mice was 
somewhat unexpected. The CD8 T cells persist at a low level long term. To test whether 
or not the T cells remained functional, I conducted two pilot experiments where I 
transplanted human skin grafts onto NSG-KDnull mice. Previous research using the NSG 
Hu-PBL-SCID model has shown that the human T cells are capable of rejecting human 
skin grafts (307). After the human skin grafts had healed onto the mice, the mice were 
injected with. The CD8 T cells engrafted and were capable of rejecting the skin graft 
while the NSG-KDnull mice maintained their bodyweight and did not show any other 
outward signs of GVHD while the skin graft was rejected. These preliminary experiment 
contained low numbers of mice but strongly suggest that the CD8 T cells are functional 
despite their long-term persistence in an environment that lacks MHC-1. This is a prime 
example of the utility of this model to examine human CD8 T cell function and its 
dependence on extrinsic factors. 
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Previously, rejection studies of different tissues have been conducted using the Hu-PBL-
SCID model. The persistent problem with this model, however, is that the tissue rejection 
occurs within the wider context of a global xenogeneic-GVHD. Xenogeneic GVHD, as 
shown in chapter 2, has wide reaching effects and even when CD8e T cells are engrafted 
into normal NSG mice, the animals clearly show symptoms of GVHD as early as 2 weeks 
and the T cells are shifted towards a more activated phenotype. Such changes have a high 
chance of masking any subtle changes that may occur in the engrafted T cells as a result 
of rejecting an implanted tissue within this context of global inflammation. What has 
been described here presents the possibility of a more nuanced approach to studying 
transplantation tolerance using the PBL-SCID model. Our lab has previously published 
similar research showing that CD4 T cells can engraft in a strain of NSG mouse that lacks 
the expression of MHC-II (NSG-ABO) (212). Crossing the NSG-ABO and the NSG-
KDnull mice to produce a MHC-I/MHC-II deficient strain of NSG mouse would 
potentially create a strain of mouse that will still engraft with human CD4 and CD8 T 
cells in the absence of xenogeneic GVHD. Based on my research here and previously 
published findings, we could potentially use this strain to produce a NSG Hu-PBL-SCID 
model that is xenogeneic GVHD resistant. Such resistance would make it a more 
attractive host for both CD4 and CD8 T cells to study the survival and the function of 
mature human T cells. Specifically, we could use this MHC-I/MHC-II deficient mouse as 
a recipient for human CD4 and CD8 T cells in addition to tissues or tumors and study 
rejection directly without such confounding factors as the background inflammation due 
to the xenogeneic-GVHD.  
? ???
Treg function and dependence on IL-2 
 
It has long been known that there is a vital role for IL-2 in the generation, maintenance, 
and function of Treg. Because of this fact, IL-2 has become a popular target for clinical 
trials to alleviate autoimmune conditions, facilitate better outcomes during 
transplantation, or suppress Treg function during cancer treatment. The danger of altering 
pleiotropic cytokines, however, is that there is always a strong risk of unintended 
consequences. The NSG BLT model showed that exogenous IL-2, in addition to 
increasing the level of Treg, greatly increased the number of NK cells in the spleen. In 
our model there was no obvious negative consequence of this increase, but this finding 
should counsel caution when using IL-2 in a clinical setting. This caution is even more 
important in autoimmune conditions where NK cells are known or suspected to play a 
role in the pathology.  In addition to caution, this model has also demonstrated that the 
BLT mice are effective tools in the testing of preclinical treatments, particularly those 
that target the immune response.  
 
Limitations of the current model 
CD8 T cell function and homeostatic proliferation 
Our current humanized models have demonstrated that HLA expression and the presence 
of IL-2 is necessary for optimal engraftment. We have limited information on why some 
CD8 T cells are able to not only persist but proliferate and, in some instances, cause a 
GVHD-like disease in MHC-I-expressing mice. The NSG-KDnull mice still express the 
? ???
B2m protein which is involved in some non-classical MHC-I antigen presentation. This 
might be an unaccounted for factor that effects both CD8 T cell function and 
proliferation. The B2M strain of mice, however, has some difficulty breeding and NSG 
mice from this strain are generally smaller in size as B2M is involved in some non-
immunological processes such as iron transportation. Because of this, it is difficult to 
determine to what extent, if any, non-classical antigen presentation is playing in the 
homeostatic proliferation of CD8 T cells within the context of our model.  
 
Treg dependence upon IL-2 for function and proliferation 
Treg depend upon IL-2 for both survival and to maintain a suppressive phenotype. In our 
experiments we used an in vivo model of allogeneic rejection to determine to what extent 
the suppressive function of Treg had changed. Because of the nature of our model 
system, specifically we had a set of NSG-BLT mice with more systemic IL-2 than the 
control group, there is the possibility that the presence of IL-2 impacted the survival of 
our allograft. To partially address this concern, we depleted CD4 cells in an additional 
experiment and saw that the allograft rejection returned to a more baseline state. 
However, this specific approach does not directly address the different levels of IL-2. 
To address this issue, we would need a more specific control for this difference in 
cytokines. One possibility would be to use an inducible source of IL-2 that could be 
turned off at the time the allograft is introduced. By allowing the IL-2 to expand the Treg 
in one group and then returning the IL-2 level to baseline, we could then directly compare 
the impact of Treg on allograft survival independent of differences in IL-2.  
? ???
Future Directions 
Elucidating more of the nuanced functions of CD8 T cell survival and function using 
the humanized mouse model 
 
CD8 T cells are capable of engrafting into NSG mice if supported by either a CD4 or 
CD8-/CD4- population of cells. This support need not be present long term and irradiated 
cells are capable of supporting CD8 engraftment. Likewise, HLA and/or MHC- I also 
assist in the engraftment and is crucial for mediating function as determined by the 
presence or absence of GVHD. Despite this information, we are left with several 
questions that have yet to be answered. These studies have looked at the engraftment of a 
heterogeneous population of mature T cells and have identified a trend towards an 
increase in the proportion of activated (CD45RO+/CD45RA- or HLA DR+) T cells but 
we have not determined whether or not naïve cells are becoming activated or if the 
memory cells within the injected population of cells are preferentially surviving in this 
environment. Regardless of the origin, I showed that the injected CD8 T cells can persist 
long term in MHC-I deficient NSG mice despite the lack of TCR stimulation. Although 
these cells are persisting in the mice, it is unknown how functional these CD8 T cells are 
given the overall lack of signals that normally ensure survival. As mentioned above, I 
conducted pilot experiments in the NSG-KDnull that looked at whether or not the CD8e 
cells could reject a human skin graft. A similar approach could be used to test if the CD8e 
cells that persist in the NSG-KDnull mice are still functional despite the lack of TCR 
stimulation. To address this, there are several avenues that we could take to further 
? ???
determine what cells survive within the context of the NSG Hu-PBL-SCID model. 
Specifically, we know that there is a general trend towards T cells with an activated 
phenotype dominating later during the engraftment phase in both the MHC-I sufficient 
and the MHC- I deficient NSG mice. Another approach to test how functional these cells 
are would be to collect splenocytes from the CD8e engrafted NSG KDnull mice and test 
their ability to kill in vitro (308) compared to splenocytes from a CD8e engrafted NSG 
mouse. 
 
There is reason to believe that the populations that survive and engraft in the normal and 
the MHC-I knockout animals may differ. To test this, we can separate the PBMC input 
into purified CD8p cells and separate them into naïve (CD45RA+/CD62L+) and memory 
(CD45RA-/CD62L-) and inject these two populations into NSG and NSG KDnull mice 
with irradiated CD4 cells or non-T cells to support engraftment and compare the 
engraftment between the 4 groups to determine if MHC is more important for the survival 
of naïve cells when compared with memory phenotype cells. 
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